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ABSTRACT OF DISSERTATION

EXPRESSION AND SPLICING OF ALZHEIMER’S DISEASE RISK GENE
PHOSPHATIDYLINOSITOL-BINDING CLATHRIN ASSEMBLY PROTEIN

Recent Genome Wide Association Studies (GWAS) have identified a
series of single nucleotide polymorphism (SNP)s that are associated with
Alzheimer’s disease (AD). One of the SNPs, rs3851179 (G/A), is near the gene
phosphatidylinositol-binding clathrin assembly protein (PICALM). To evaluate
whether this SNP is associated with PICALM expression, we quantified PICALM
mRNA in 56 brain cDNA samples. Using linear regression analysis, we analyzed
PICALM expression relative to rs3851179, AD status, and cell type specific
markers. An association was detected between rs3851179 and PICALM,
microvessel mRNA, glial fibrillary acidic protein (GFAP) mRNA, and
synaptophysin (SYN) mRNA. To gain clarity into other possible SNP
mechanisms, we searched brain cDNA for PICALM splice variants. We identified
several PICALM splice variants involving exons 13-19. To identify and gain an
estimation of relative abundance of splice variants, we PCR-amplified across
exons 13-20 in cDNA from six individuals, three rs3851179 GG individuals and
three rs3851179 AA individuals. Sequencing the cloned isoforms we found that
PICALM lacking exon 13 (delta 13) is the most abundant isoform. Other isoforms
detected included deletion of exon 18-19. We targeted the latter part of the gene,
exon 17-20, to investigate unequal allelic expression using next generation
sequencing. Individuals heterozygous for rs76719109 (n= 35), located in exon
17, were used to study the abundance of G/T allele in cDNA and genomic DNA.
When we analyzed the T:G allelic ratio, the variant lacking exons 18 and 19
showed unequal allelic expression (p-value < 0.001) in a subset of individuals.
One individual was an outlier, showing overall unequal allelic expression, which
maybe be harboring a rare mutation capable of modifying PICALM expression.
The PICALM intronic SNP rs588076 was associated with delta 18-19 isoform
splicing (p-value < 0.001). In conclusion, this study gained a greater insight into
the role of AD genetics in PICALM expression and splicing.

KEYWORDS: PICALM, Alzheimer’s disease, Next-generation sequencing, allelic
expression imbalance, single nucleotide polymorphism
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Chapter 1
Introduction

Alzheimer’s Disease

Impact
Alzheimer’s Disease (AD) is a complex disease with a genetic component
that affects the aging population. An estimated 5.2 million people in the United
States and 35.6 million worldwide are affected by the disease. Although
dementia is seen in various neurodegenerative diseases, with an estimate that
one in eight older Americans is diagnosed with dementia, AD is the most
common cause of dementia. Prevalence of the disease will increase as the
world’s population ages and lives longer due to better healthcare and medical
advances. Recent projections indicate that by 2030, when the baby boomers will
be at least 65 years old, there will be more than a 50% increase from the current
5.2 million people affected. The burden of AD treatment cost can be felt both by
healthcare programs, as well as the family and friends of the patient that provide
care while forsaking their income and financial security for a challenging and
stressful environment. The combined direct and indirect cost of AD is estimated
to be $214 billion and the projected cost for 2050 balloons to 1.2 trillion dollars
(Fargo & Bleiler, 2014).
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History
In 1901, the first case of AD was identified in patient Auguste Deter by
German psychiatrist Alois Alzheimer. Alzheimer followed the case until her death
in 1906. Through Alzheimer’s extensive notes we know that Auguste exhibited
memory deficits, cognitive decline, and paranoia. The autopsy of Auguste’s brain
showed atrophy and arteriosclerosis of blood vessels (Maurer, Volk, & Gerbaldo,
1997). Alzheimer’s observed, described and illustrated numerous neurofibrillary
tangles

and

amyloid

plaques.

Thus

patients

with

dementia

and

this

neurohistological pathology have subsequently been diagnosed with a disease
that bears his name, Alzheimer’s Disease. Although AD is the most common
cause of dementia, there are other types of dementia that can be present, such
as vascular dementia or frontotemporal lobar degeneration. Thus an autopsy is
the only definitive way to diagnose AD.

Diagnosis
Clinically, AD and other causes of dementia are diagnosed by neurological
exam and mental status tests. One of the commonly used mental exams is the
Mini-mental state exam (MMSE), where a patient answers a series of questions
designed to test cognition. It tests the patient’s ability to follow verbal and written
commands, as well as memory, attention, and orientation. The total maximum
score for the test is 30 (Folstein, Folstein, & McHugh, 1975). An MMSE score of
less than 12 suggests severe dementia, whereas 13-20 is considered moderate
and 20-24 is mild cognitive decline (Fargo & Bleiler, 2014).

Histopathologically, the brain is evaluated for neurofibrillary tangles and
senile plaques to be diagnosed for AD. Braak Stage classifies extent of
neurofibrillary tangle accumulation and distribution. There are a total of six Braak
stages, and severity of diagnosis increases with each stage (Braak & Braak,
1991). The Consortium to Establish a Registry for Alzheimer’s disease (CERAD)
2

score evaluates and ranks the density of neuritic plaques in the brain (Mirra et
al., 1991). Lastly, NIA-Reagan Institute Criteria (NIARI) combines both the
CERAD and Braak stage scores and evaluates patient’s likelihood of AD
neuropathologically (Hyman & Trojanowski, 1997).

Although amyloid plaques and neurofibrillary tangles are two hallmarks of
AD, there are other lesser known lesions and proteins that are also seen in AD;
such as Hirano bodies, TDP-43, Lewy bodies and granulovacuolar degeneration
(Perl, 2010; Wilson, Dugger, Dickson, & Wang, 2011). Diagnosis of AD is varied
and through clinical and histopathological criteria, clinicians and researchers aim
to have a more concise conclusion of diagnosis. Apart from the neurological
exams, clinicians have limited tools to diagnose AD. Currently, there are no
biomarkers or imaging tools to diagnose AD. Cerebrospinal fluid (CSF) Aβ40 and
Aβ42 levels are being examined by researchers and clinicians as a tool to
diagnose AD and assess the progression of mild cognitive impairment to AD.
Having a more sensitive assessment of AD outcome could lead to early detection
and a better therapeutic profile (Shaw et al., 2009). Decreased levels of Aβ42 in
CSF have been seen as a biomarker of AD-related pathologic changes in the
brain; suggesting more accumulation of Aβ in the brain and less clearance
(Blennow & Hampel, 2003). Neuroimaging is also another venue for AD
diagnosis. Pittsburgh compound B (PiB) is a radioactive compound that binds to
amyloid plaque. PiB has shown promising results in imaging amyloid deposits in
brain scans in patients (Klunk et al., 2004). The amount of amyloid plaque load in
a brain scan, in combination with Aβ1-42 in CSF could pave way to helping
diagnose patients at an earlier stage of AD.

Etiology
Neuritic or senile plaques consist of amyloid beta peptide (Aβ) aggregate
deposits in the extracellular matrix of brain. Aβ peptide is a fragment of the
Amyloid Precursor Protein (APP) (Glenner & Wong, 1984; Kang et al., 1987).
3

Located on the long arm of chromosome 21, APP is a highly conserved gene
presenting multiple isoforms. Although APP is ubiquitously expressed, it is highly
expressed in brain and kidney. In brain, APP function is still unclear. It has been
implicated in neuronal development, survival and synaptic density (Oh et al.,
2009; Roch et al., 1994; Young-Pearse et al., 2007).

APP processing is critical in developing AD (Figure 1.1). APP can be
proteolyzed by α, β, and γ-secretase to produce multiple products, including Aβ.
When APP is cleaved by β-secretase and subsequently γ-secretase, proteolysis
generates Aβ peptide that is 39-42 amino acids. Aβ42 is the more toxic species of
these peptides; they aggregate and form plaques in the extracellular space.
Although Aβ42 only accounts for 10% of the Aβ peptide product, it is associated
with AD plaque pathology; because of its hydrophobic nature it is more inclined
to fibril formation, and resist proteolytic degradation and clearance (Burdick et al.,
1992; Selkoe, 1998). High Aβ load has been shown to disrupt synaptic function
and cause neuronal death (Deshpande, Mina, Glabe, & Busciglio, 2006; Shankar
& Walsh, 2009). A tremendous amount of research has been done on the
amyloid cascade pathway, however the role environmental and genetic factors
play in APP processing and Aβ aggregation in propagating sporadic AD is still
unclear.

Neurofibrillary

tangles,

another

hallmark

of

AD,

consists

of

hyperphosphorylated tau protein within the neuronal cytoplasm. Tau is a
microtubule binding protein found mostly in neuronal cells axons and functions to
stabilize microtubules. Alternate splicing of microtubule-associated protein tau
(MAPT) gene, located on chromosome 17, produces multiple isoforms with
variable microtubule-binding and phosphorylation sites (Hanger et al., 2007).
When attached to the microtubules, tau allows the microtubules to be structured
tracks for axonal transport of vesicles. Typically, tau detaches from the
microtubules temporarily when phosphorylated, allowing for flexibility. When tau
protein is hyperphosphorylated, it destabilizes and detaches from the
4

microtubules, causing tau aggregates to form within the neuron (Grundke-Iqbal et
al., 1986; Schneider, Biernat, von Bergen, Mandelkow, & Mandelkow, 1999).
Tau tangles have also, like Aβ, been associated with neuronal death and
synaptic dysfunction (Gamblin et al., 2003; Tai et al., 2012). AD brains have
more abundant and different phosphorylation sites; current therapeutic targets
focus on modulating tau phosphorylation through specific kinase inhibitors
(Hanger et al., 2007; Mudher et al., 2004; Noble, Hanger, Miller, & Lovestone,
2013).

Susceptibility
There are two forms of AD: early onset AD and late onset AD. Early onset
AD or familial AD (FAD) is a rare form of AD and is characterized by being
affected by dementia at a young age (younger than 65 years old). FAD can have
Mendelian autosomal dominant form of heredity and can be passed on through
generations.

Through

genetic

linkage

analysis

studies

gene

mutations

responsible for FAD were discovered. A missense mutation near the β-secretase
cleavage in APP was the first mutation associated with FAD (Goate et al., 1991).
Mutations in primarily three genes have been linked to FAD: APP, Presenilin-1
(PSEN1), and Presenilin-2 (PSEN2) (Schellenberg et al., 1992; Sherrington et
al., 1995). Since the early 90s, many mutations have been linked with FAD,
involving APP processing and Aβ production, particularly near enzymatic
cleavage sites. Currently, there are 238 mutations residing in these three genes
that have been studied for AD. PSEN1 exhibits 185 mutations with pathogenic
effect and is represented highest in familial genetic screening (Cruts, Theuns, &
Van Broeckhoven, 2012). There are other genes with mutations that have been
linked to FAD to a lesser extent, such as FUS, GRN, MAPT, TARDBP, VCP and
C9orf72. PSEN1 and PSEN2, located on chromosome 14 and 1, respectively,
are part of γ-secreatase complex that cleaves APP to subsequently produce Aβ.
Mutations within these genes have been shown to increase Aβ40/Aβ42 ratio
(Steiner, 2004). Mutations in MAPT have also been linked to FAD, thus piquing
5

researchers’ interest in studying genotype influencing the development of
pathogenic phenotype, specially in Late On-set AD (LOAD) (Cruts et al., 2012).

LOAD is the sporadic form of AD with age of onset being 65 or older.
LOAD accounts for up to 95% of AD cases (Eisenstein, 2011). Twin studies
suggest that approximately 79% of AD is genetic (Avramopoulos, 2009; Gatz et
al., 2006). A primary genetic risk factor for AD is apolipoprotein E (APOE). Three
most common variants of APOE include E2, E3, and E4; one copy of E4
increases AD risk by 4 fold and two copies by 12-fold (Eisenstein, 2011; O'Brien
& Wong, 2011). APOE gene is found on chromosome 19 and encodes for a
protein that facilitates the transport of lipoproteins throughout the body.

APOE is primarily produced by microglia and astrocytes in the brain.
There are several proposed mechanisms through which APOE can modulate AD
pathology. The primary result shows Aβ clearance is influenced in APOE allele
dependent manner, where Aβ clearance is disrupted by E4 the most. Aβ binds
lipidated APOE and is cleared through the blood brain barrier (Liu, Kanekiyo, Xu,
& Bu, 2013)
Beyond APOE, researchers have struggled to find single nucleotide
polymorphism (SNP)s that influence AD onset. It has been difficult to identify
genes or genetic factors that modulate the disease. Although these variants
alone are variable in the whole disease population, however the combination of
different sporadic SNPs may be carried by AD population that affect a gene or
genes in the same pathway and consequently influence disease onset and
progression. Due to the heterogeneity of AD, it has been difficult to find risk
genes with small cohorts and with enough statistical significance.

Genetics of AD
Genome-wide association studies (GWAS) have revolutionized the search
for low penetrative alleles that influence risk for complex diseases and traits.
Associations made between the genetic variations and phenotype are within a
6

large sample size and span the whole genome, enabling researchers to discover
risky or protective loci. Over the last couple of years, GWAS have identified many
risk loci and candidate genes for AD by genotyping SNPs in AD and non-AD
groups. (Bertram, McQueen, Mullin, Blacker, & Tanzi, 2007). APOE remains the
highest risk factor for AD within GWA studies, but loci around BIN1, CLU,
ABCA7, CR1, PICALM, MS4A6A, CD33, MS4A4E, and CD2AP have been
implicated in AD and are currently the top ten risk genes on Alzgene (Bertram et
al., 2007). As more studies are conducted in different cohorts and populations,
additional loci have been implicated in AD, including EPHA1, INPP5D, MEF2C,
HLA-DRB1-HLA-DRB5, NME8, SLC24A4/RIN3, ZCWPW1, PTK2B, SORL1,
CELF1, FERMT2, DSG2 and CASS4 (Lambert et al., 2013).

Understanding how these SNPs are associated with AD is complex for
several reasons. First, the association of these SNPs with AD risk does not
indicate causality of AD phenotype or pathology. Rather, these SNPs contribute
to risk and have low penetrance. Second, discerning the gene associated with
the AD-associated SNP is challenging if multiple genes are present within the
same genetic linkage disequilibrium (LD) block as the implicated SNP. Third, a
large number of these SNPs are not genotyped but imputed based on their LD
with a genotyped SNP. Thus there is ambiguity about the functional SNPs and
genes associated with AD. As more GWA studies and meta-analysis studies are
conducted there is more confidence within loci. Lastly, the effect of these SNPs
on AD risk is small such that the accumulated risk of these SNPs may be more
relevant.

Considering that many of the SNPs implicate genes within similar

pathways, such as cholesterol homeostasis, inflammation and endocytosis, some
interaction among the SNPs within a pathway may become clear with further
studies. Of particular relevance here, several SNPs in genes associated with
endocytosis have been associated with AD, including SNPs within BIN1, CD2AP,
and PICALM.
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PICALM is associated with LOAD through multiple GWAS studies.
PICALM is located on chromosome 11 with the primary SNP, rs3851179,
~80,000bp 5’ upstream of PICALM. The minor allele of this SNP reduces AD risk
with an odds ratio ~0.88. Several other PICALM SNPs have also been
associated with AD risk: rs561655, rs592297 and rs541458 (Corneveaux et al.,
2010; Harold et al., 2009; Hollingworth et al., 2011; Jun et al., 2010; Lambert et
al., 2013; Naj et al., 2011; Schjeide et al., 2011). The initial studies were primarily
performed with Caucasian populations, however when studies were replicated
and/or performed with different populations, there was no association found
between AD risk and SNP in Italian, Hispanic, and Chinese populations (Lee et
al., 2011; Piaceri et al., 2011; Yu et al., 2011). This difference can be interpreted
as either (i) the SNP effect may be population specific or (ii) these conflicting
results maybe due to small sample size of the studies, as positive associations
were seen in other studies and meta-analysis (Feinkohl et al., 2013; T. Jiang et
al., 2014; G. Liu et al., 2013; Miyashita et al., 2013)

Clathrin Mediated Endocytosis and PICALM
PICALM functions to assist in clathrin coated pit formation. Normal
regulation of Clathrin Mediated Endocytosis (CME) is critical for cellular
homeostasis. CME is essential for cellular functions such as cell-to-cell
communication, cell surface protein regulation and protein recycling. Different
proteins facilitate clathrin coat formation through distinct stages of coat
development (Ramanan et al., 2011b). These proteins, including PICALM, are
collectively called clathrin assembly proteins. PICALM binds phosphatidylinositol
4,5-bisphosphate (PIP2), adaptor protein 2 (AP2), and clathrin. PIP2 is abundantly
present in plasma membrane. Clathrin and AP2 are involved in the early phase of
vesicle formation, which consists of nucleation and invagination. PICALM
contains a N-terminal globular PIP2 binding module called ANTH (AP180 Nterminal Homology) domain (Dreyling et al., 1996). PICALM motifs that bind AP2
8

include

375

DIF,

420

DPF and

489

FESVF, which are encoded by exons 11, 13, and

14, respectively. PICALM motifs that bind clathrin are primarily in the PICALM Cterminal region and secondarily a weak binding site at the

392

DLLDLQ motif

encoded by exon 12 (Dreyling et al., 1996; Meyerholz et al., 2005) (Figure 1.2).
Organization of the clathrin coat is influenced by PICALM as the size and shape
of clathrin-coated vesicles is altered with overexpression or knockdown of
PICALM (Meyerholz et al., 2005; Tebar, Bohlander, & Sorkin, 1999).

PICALM and AD
APP trafficking and cleavage appears central to development of AD. CME
plays a role in APP internalized from the cell membrane and subsequent amyloid
beta generation, suggesting a possible relationship PICALM could have with AD.
CME proteins, including PICALM, are significantly increased in transgenic mice
AD (Koo & Squazzo, 1994; Thomas, Lelos, Good, & Kidd, 2011). In neurons,
PICALM has been shown to influence cell surface protein endocytosis and
recycling (Harel, Mattson, & Yao, 2011). The function of PICALM in AD is
perplexing. There are conflicting results on how PICALM could modulate AD
pathology. In yeast, mice and rat models, increased PICALM has been shown to
increase Aβ production (Treusch et al., 2011; Xiao et al., 2012). However, in
vitro show that increased PICALM results in decreased endocytosis of transferrin
(Tebar et al., 1999). It has been proposed that PICALM may function in a cargo
specific manner.

Significance of the Study
Recent advances in GWAS have provided insights into AD genetics.
GWAS scans though the human genome for SNPs which associate with disease.
Recent studies with large populations identified several risk genes for AD,
including PICALM. Though these SNPs may have a modest effect, they have
been replicated with significance numerous times in different populations.
Although GWAS can identify genetic variant associations, there is a lack of
functional link between the genetic variants and AD. This study aims to
9

characterize the link between PICALM genetic association with AD. PICALM is
part of the clathrin assembly protein family and the encoded protein assists in
clathrin coat formation in clathrin-mediated endocytosis. PICALM assists clathrin
coat formation by scaffolding AP2 and clathrin to generate a clathrin coated pit.
Genetic variant rs3851179, located upstream of PICALM, was associated with
AD. In this study we hypothesize that rs3851179 is associated with PICALM
expression or splicing.

10

Figure 1.1 APP Processing.
In the non- amyloidogenic pathway, APP is proteolytically cleaved by
αsecretase and subsequently by γ secretase to produce soluble APP (s-APP
αandp3, respectively. In the amyloidogenic pathway, APP is cleaved by β
secretase and γ secretase resulting in s-APP β and Aβ fragment, respectively.
Accumulation of Aβ fragments results in amyloidogenic plaque.
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Figure 1.2 PICALM Exons, Protein Binding Sites and Critical Protein Motifs
PICALM encodes protein motifs and domains important for binding to PIP2, AP2
and clathrin. This gene schematic shows the 21 PICALM exons. N-terminus of
PICALM binds PIP2 via the ANTH domain. ANTH domain is encode by several
exons, diagram not to scale. Three motifs important for effective PICALM binding
to AP2 is encoded by exons 11, 13, and 14 and c-terminus of PICALM binds to
clathrin (Meyerholz et al., 2005).

Copyright © Ishita Jatin Parikh 2014
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Figure 1.3 PICALM Pathogenic model
Clathrin and cargo molecules are assembled into clathrin-coated pits on the
plasma membrane together with an adaptor protein 2 (AP2) that links clathrin with
transmembrane receptors, concluding in the formation of mature clathrin-coated
vesicles (CCVs). CCVs are then actively uncoated and transported to
early/sorting endosomes. PICALM binds to PIP2 on the plasma membrane, while
also binding with AP2 and clathrin.
Adapted from: (Bali et al., 2010)
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Chapter 2
Genetics of PICALM Expression and Alzheimer’s Disease

Abstract
Novel Alzheimer’s disease (AD) risk factors have been identified by
genome-wide association studies. Elucidating the mechanism underlying these
factors is critical to the validation process and, by identifying rate-limiting steps in
AD risk, may yield novel therapeutic targets. Here, we evaluated the association
between the AD-associated polymorphism rs3851179 near PICALM, which
encodes a clathrin-coated pit accessory protein. Immunostaining established that
PICALM is expressed predominately in microvessels in human brain. Consistent
with this finding, PICALM mRNA expression correlated with expression of the
endothelial genes vWF and CD31.

Additionally, we found that PICALM

expression was modestly increased with the rs3851179A AD-protective allele.
Analysis of PICALM isoforms found several isoforms lacking exons encoding
elements previously identified as critical to PICALM function.

Increased

expression of the common isoform lacking exon 13 was also associated with the
rs3851179A protective allele; this association was not apparent when this
isoform was compared with total PICALM expression, indicating that the SNP is
associated with total PICALM expression and not this isoform per se.
Interestingly, PICALM lacking exons 2-4 was not associated with rs3851179 but
was associated with rs592297, which is located in exon 5. Thus, our primary
findings are that multiple PICALM isoforms are expressed in the human brain,
that PICALM is robustly expressed in microvessels, and that expression of total
PICALM is modestly correlated with the AD-associated SNP rs3851179. We
interpret these results as suggesting that increased PICALM expression in the
microvasculature may reduce AD risk.
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Introduction
Alzheimer’s disease (AD) is a devastating disease marked by cognition
and memory decline, affecting the elderly population. Twin and family-based
studies suggest that sporadic late onset AD risk is genetically linked
(Avramopoulos, 2009; Gatz et al., 2006).

Recent genome wide association

studies (GWAS) have identified loci of genetic variance, single nucleotide
polymorphisms (SNP)s, that are associated with AD risk (Harold et al., 2009;
Hollingworth et al., 2011; Jun et al., 2010; Lambert et al., 2009; Lambert et al.,
2011; Naj et al., 2011). Elucidating the mechanism of action of these SNPs
validates the SNP as an AD risk factor and may identify novel AD pathways.
Additionally, since steps in AD pathways that are modulated by genetics may be
susceptible to pharmacologic manipulation, identifying the actions of ADassociated SNPs may lead to robust new pharmacologic targets.

One of these SNPs is near the gene PICALM (phosphatidylinositol binding
clathrin assembly protein) which is involved in endocytosis. The primary ADassociated SNP is rs3851179, which lies approximately 80 kb 5’ of
PICALM(Hollingworth et al., 2011; Morgan, 2011; Naj et al., 2011). PICALM itself
is encoded by 21 exons, several of which are variably spliced (Flicek et al.,
2014). Here, we sought to elucidate how rs3851179 alters PICALM expression or
splicing to modulate AD risk. We report that PICALM is expressed robustly in
microvessels and moderately in other cell types.

Rs3851179 was modestly

associated with total PICALM expression as well as the major PICALM isoform
lacking exon 13. In contrast, the expression of rare PICALM isoforms lacking
exons 2, 2-4, or 18-19 was not associated with rs3851179. We interpret our
results as suggesting that the PICALM is robustly expressed in microvessels and
that the protective rs3851179A allele is associated with modestly increased
PICALM expression. We speculate that increased microvessel PICALM reduces
AD risk, perhaps by facilitating Aβ clearance from the brain through enhanced
translocation across the blood brain barrier.

15

Materials and Methods
Ethics Statement
The work described here was performed with approval from the University
of Kentucky Institutional Review Board.

Tissue samples
The RNA and DNA samples for this study were from de-identified AD and
non-AD autopsy samples. Anterior cingulate specimens were provided by the
University of Kentucky AD Center Neuropathology Core and have been
described previously (Ling, Bhongsatiern, Simpson, Fardo, & Estus, 2012; Malik
et al., 2013). A total of 52 brain samples, 28 male and 24 female, were used for
this study. All of the non-AD individuals were cognitively intact at their last visit
(MMSE of 27.9 ± 3.4 (mean ± SD)). AD individuals were demented (MMSE of
12.2± 8.3).

For the AD autopsy samples, the average age at death and

postmortem interval was 82.9 ± 6.4 years (mean
respectively.

± SD) and 3.4 ± 0.7 hrs,

For the non-AD samples, the average age at death and

postmortem interval was 82.3 ± 8.7 years (mean

± SD) and 2.8 ± 0.8 hrs,

respectively. By NIARI neuropathology criteria, the non-AD individuals included
21 samples with a score of no-low likelihood of AD, and 6 with intermediate. The
AD samples were uniformly high-likelihood of AD. RNA was prepared by the
method of Chomczynski and Sacchi (Chomczynski & Sacchi, 1987) and
converted to cDNA with random hexamers and Superscript II, as described
previously (Ling et al., 2012).

Although RNA integrity analyses were not

performed prior to reverse transcription, others have demonstrated that for qPCR
with short amplicons, normalized expression differences are comparable
between samples with moderate RNA degradation and those with high integrity
RNA (Fleige & Pfaffl, 2006).
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PICALM immunostaining
Paraffin-embedded anterior cingulate tissue sections (5 µm thick) were
rehydrated, underwent heat-induced antigen retrieval in citrate buffer (pH 6.0)
and were quenched in 0.3% H2O2. Sections were immersed in 10% rabbit serum
in Tris-buffered saline followed by an overnight incubation in anti-CALM (sc6433, Santa-Cruz; 1:400 dilution). After thorough rinsing in Tris-buffered saline,
sections were incubated in biotinylated secondary antibody for 1 h, rinsed,
incubated in ABC reagent (Vector) for 1 h, developed in Nova Red chromagen
(Vector) and counterstained with Hematoxylin.

Identification of PICALM Splice Variants in Human Brain
Screening for PICALM splice variants was performed on a pool of cDNA
samples from five AD and five non-AD individuals. This cDNA pool was amplified
by PCR by using forward and reverse primers designed to produce overlapping
products; this enabled evaluation of splicing efficiency of each internal exon
(Table 2.1). The identity of splice variants was determined by sequencing. To
estimate the distribution of these splice variants, exon 12-20 PCR products from
three rs3851179 homozygous minor (A/A) and three homozygous major (G/G)
individuals were TA-cloned (Invitrogen) and 847 random clones were sequenced.
For this work, thirty cycles of PCR (Platinum Taq, Invitrogen) were performed by
using primers corresponding to exons 12 and 20 (Table 2.1). PCR conditions
were 94° for 15 seconds, 60° for 15 seconds, and 72° for 60 seconds (Veriti 96Well Thermal Cycler, Life Tech). PCR was conducted using approximately 30 ng
of cDNA template. After PCR, samples were cloned into pcDNA2.1 according to
the manufacturer’s instructions (TA-Cloning Kit, Invitrogen) and sequenced.

Quantitation of PICALM Expression
Total PICALM expression was quantified by qPCR using primers
corresponding to sequences within the constitutively present exons 9 and 10
(Table 2.1); PICALM isoforms lacking exon 2, exons 2-4, 13 or 18-19 were
quantified similarly (Table 2.1). As no single Ensembl transcript incorporates
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each of the exons that we identify here, note that our exon designations are
derived from ENST00000393346 for exons 1-16. Exons 17-21 correspond to the
final five exons within ENST00000532317. PCR was conducted using an initial 2minute incubation at 95°, followed by cycles of 10 seconds at 95°, 20 seconds at
60°, and 20 seconds at 72°. The 20 µL reactions contained 1µM of each primer,
1x PerfeCTa SYBR Green Super Mix (Quanta Biosciences), and 30 ng cDNA.
Experimental samples were amplified in parallel with serially diluted standards
that were generated by PCR of cDNA using the indicated primers followed by
purification and quantitation by UV absorbance. Results from samples were
compared relative to the standard curve to calculate copy number in each
sample. Real time assays were performed at least twice and the average copy
number used for data analyses. Since PICALM was expressed in microvessels,
neurons and astrocytes, we wished to compare PICALM expression to that of
genes specific to these cell types. Hence, we also quantified two microvesselspecific mRNAs, CD31 and von Willebrand Factor (vWF), neuron-specific mRNA
SYP and astrocyte-specific GFAP. (Jackson, 2003; Sadler, 1998). The copy
number for each mRNA was then normalized to the geometric mean of reference
genes RPL32 and EIF4H, previously quantified in this sample set (Ling et al.,
2012; Malik et al., 2013). The linear regression statistical model used to analyze
the data included the geometric mean of CD31 and vWF (microvessel mRNA),
GFAP, SYP, AD status and the number of rs3851179 minor alleles (SPSS
version 21).

Results
To begin to evaluate the role of PICALM in AD, we localized PICALM
expression in human brain by performing immunohistochemistry. We used an
antibody that recognizes an epitope at the extreme PICALM carboxyl terminus
that is found in all PICALM isoforms (see below). Robust PICALM expression
was observed in microvessels in both non-AD and AD brain sections (Figure
2.1). Consistent with other reports, we also observed less robust PICALM
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immunostaining in other cell types that have been identified as neurons and glia
(Ando et al., 2013; Baig et al., 2010).

To elucidate the impact of the primary AD-associated SNP rs3851179 on
PICALM, we chose a three-tiered approach. First, we evaluated whether a nonsynonymous PICALM SNP was in linkage disequilibrium with rs3851179. The
rs3851179 minor allele frequency in European Americans is 35%. According to
the Exome Variant Server (http://evs.gs.washington.edu/EVS/), there are no nonsynonymous PICALM SNPs with a minor allele frequency above 0.2% ("Exome
Variant Server,"). Hence, the rs3851179 association with AD is not likely to be
explained by a non-synonymous PICALM SNP.

The second tier of our approach to elucidate SNP action was to evaluate
the extent that PICALM expression correlated with rs3851179 genotype and/or
AD status. To this end, total PICALM expression was quantified in 52 brain
samples by using qPCR and primers corresponding to sequences within exons 9
and 10 which are constitutively present (see below). PICALM copy number was
normalized to the geometric mean of two housekeeping genes, RPL32 and
eIF4H (Ling et al., 2012; Malik et al., 2013). Inspection of the results supports
that total PICALM expression correlated positively with microvessel mRNA
expression (Figure 2.2A).

To evaluate the statistical correlation between

PICALM expression and relevant indices, we analyzed PICALM expression
relative to AD status, rs3851179 genotype, and several cell-type specific mRNAs.
Linear regression analysis found an overall significant model (adjusted R2=0.46)
with a significant correlation between PICALM and rs3851179 as well as cell type
markers but not AD (Table 2.2). Rs3851179, GFAP and microvessel mRNA
correlated positively with total PICALM expression, whereas SYP showed
negative correlation. The AD-protective, minor rs3851179A allele was associated
with increased total PICALM expression.
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The third tier of our approach to determine possible SNP function was to
evaluate the extent that a PICALM splice variant was associated with rs3851179
genotype and/ or AD status. We began by identifying PICALM splice variants
present in human brain. PCR was performed by using a series of primer pairs
that flank PICALM internal exons, e.g., primers corresponding to exons 1 and 5
were used to evaluate whether exons 2, 3 or 4 were variably spliced. This study
found that multiple PICALM exons were inefficiently spliced (Figure 2.3).
Sequencing of the exon 1-5 amplicons found that most PICALM isoforms
contained exons 2, 3 and 4 while apparently rare isoforms lacked exon 2 or
exons 2- 4. Amplifying from exon 3 to exon 9, and exon 7 to exon 12 showed
that exons 5-11 were consistently present (Figure 2.3). This supports the use of
primers corresponding to exons 9 and 10 for qPCR for total PICALM.
Amplification reactions between exons 10-21 overall found multiple PICALM
isoforms. These isoforms were not sufficiently resolved by polyacrylamide gel
electrophoresis to allow sequencing of individual gel-purified products. To
overcome this issue, PICALM from exon 12 to exon 20 was PCR-amplified, and
the PCR products cloned and sequenced.

To gain an initial evaluation of

whether rs3851179 may be associated with PICALM splice variants, we analyzed
RNA from three rs3851179 G/G and three rs3851179 A/A homozygous
individuals. This effort revealed that exons 13, 14, 18 and 19 were inefficiently
spliced. The most common PICALM variant lacked exon 13 and contained each
of the other exons from 12 to 20 (Table 2.3). Other common variants contained
each exon from 12-20, or lacked exon 13 and the initial 15 bp of exon 15, or
lacked both exon 13 and 18. A comparison of the abundance of each isoform in
rs3851179G/G versus rs3851179A/A individuals did not reveal striking
differences (Table 2.3).

Overall, we interpret these data as indicating that

multiple PICALM exons are variably spliced. Although these isoforms were not
associated with rs3851179 in this semi-quantitative assay, their abundance
warranted a more quantitative evaluation.

20

For quantitation, we initially focused on exon 13 because (i) this exon is
commonly skipped and (ii) this exon encodes the DPF peptide motif that
contributes to PICALM binding to AP2 (Meyerholz et al., 2005). We quantified
PICALM lacking exon 13 (D13-PICALM) by using qPCR primers corresponding
to sequences within exon 11 and the exon 12- exon 14 junction (Table 2.1). D13PICALM correlated well with total PICALM expression and constituted about 40%
of total transcript (Figure 2.2B). D13-PICALM expression was analyzed as a
function of rs3851179, AD status, and several cell-type specific mRNAs. The
expression of D13-PICALM correlated with rs3851179, AD status, as well as the
cell-type specific mRNAs (adjusted R2 =0.54, Table 2.2).

The minor

rs38555179A allele and the absence of AD correlated with increased D13PICALM expression.

To evaluate whether rs3851179 was associated with D13-PICALM
independently of the SNP association with total PICALM expression, we
analyzed D13-PICALM expression as a function of rs3851179, AD status and
total PICALM expression. With this analysis, we found that D13-PICALM was
associated with AD status and total PICALM, but not rs3851179. Hence, D13PICALM expression is associated with rs3851179 only because total PICALM
expression is associated with rs3851179.

We next analyzed PICALM splice variants that lacked exons 18 and 19
(D18-19 PICALM), noting that the PICALM carboxyl region that includes amino
acids encoded by exon 18 and 19 is critical for PICALM function (Scotland et al.,
2012). This qPCR assay used forward and reverse primers that recognized exon
17 and the exon 17 - exon 20 junction, respectively (Table 2.1). We found that
D18-19 PICALM represented 1-2% of total PICALM expression (Figure 2.2C)
and correlated with neuronal and astrocyte content but not rs3851179 (Table
2.2).

21

We next quantified isoforms that lack exon 2 (D2-PICALM). This isoform
is expected to not encode a functional protein because the loss of exon 2
introduces a codon frameshift with a premature stop codon in exon 3. Exon 2
encodes a portion of the ANTH domain that binds PIP2 on the plasma membrane
during the initial stage of clathrin-coated pit formation (Dreyling et al., 1996), We
found that D2-PICALM was typically rare, representing less than 1% of total
PICALM expression (Figure 2.2D). However, two samples showed increased
D2-PICALM expression, ranging as high as 3.6%. The reason underlying the
higher D2-PICALM in these individuals was unclear; these individuals both had
AD, they differ in sex (one female and one male), and had a post-mortem interval
similar to the other samples (2.4-4.0 hours). When these outlier samples were
excluded

from

analysis,

D2-PICALM

was

significantly

associated

with

microvessel and neuronal content, as well as AD status but not rs3851179
genotype (adjusted R2=0.41, Table 2.2).

D2-PICALM was increased in AD

individuals.

We also identified a PICALM isoform lacking exons 2-4 (D2-4 PICALM).
The D2-4 PICALM isoform was also present at low levels, with an average of
0.28 ± 0.15% (mean ± S.E.) of total PICALM expression (Figure 2.2E).
Expression of D2-4 PICALM was associated with AD but not with rs3851179 or
microvessel content, suggesting that this variant is not expressed in microvessels
(Table 2.2). Interestingly, Schnetz-Boutaud et al have reported that an exon 5
SNP rs592297 is in linkage disequilibrium with rs3851179 (D’=1, r2=0.34) and
proposed that rs592297 modulates the activity of an exon splicing enhancer
(Schnetz-Boutaud et al., 2012). Therefore we evaluated whether rs592297 was
associated with D2-4 PICALM expression. We found that rs592297 associated
with the D2-4 PICALM (Figure 2.2F, Table 2.2). Hence, higher D2-4 PICALM
expression is associated with the rs592297C minor allele. The percentage of
PICALM expressed as D2-4 PICALM was quite low but was increased from 0.23
± 0.11% in rs592297 major allele homozygous samples to 0.36 ± 0.17% in
samples with the rs592297 minor allele (Figure 2.2F, p=0.004). Although we and
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others have not examined the association of this SNP with AD directly, based on
the linkage between rs592297 and rs3851179, the minor rs592297C allele is
likely to associated with increased AD risk (Schnetz-Boutaud et al., 2012).

Discussion
The primary findings of this paper are (i) multiple PICALM isoforms are
expressed in human brain, (ii) consistent with immunohistochemistry results that
PICALM is commonly found in microvessels, expression of total PICALM and the
abundant D13-PICALM is positively correlated with the expression of microvessel
mRNAs,

(iii) total PICALM expression correlates modestly with the AD-

associated SNP rs3851179, (iv) D2-4 PICALM was associated with AD status
and an exon five SNP, rs592297, which is in linkage disequilibrium with
rs3851179 (r2=0.34). However, D2-4 PICALM was a rare isoform, suggesting
that this association is not responsible for the SNP association with AD, and (v)
two additional rare PICALM isoforms, D18-19 PICALM and D2-PICALM were
variably associated with AD and cell-specific mRNAs. Overall, we interpret our
results as suggesting that multiple PICALM isoforms are expressed in the brain,
and that correcting for cell-specific mRNAs allows the discernment that the ADprotective allele of rs3851179 is associated with increased PICALM expression.

Immunostaining showed abundant PICALM expression in microvessels.
Consistent with this observation, total PICALM expression correlated with CD31
and vWF expression, genes highly expressed in endothelial cells (Jackson, 2003;
Sadler, 1998). Hence, our statistical model for PICALM expression included the
geometric mean of these microvessel mRNAs, well as SYP and GFAP. When we
analyzed PICALM expression in this fashion, PICALM expression correlated with
rs3851179 genotype. Indeed, inclusion of the expression of these cell-type
specific mRNA is the primary difference between our study which detected an
association between PICALM expression and rs3851179 and prior studies that
did not discern this association (Allen et al., 2012; Karch et al., 2012). The
modest association that we observed may reflect that rs3851179 is not a
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functional SNP but rather is in linkage disequilibrium with SNP(s) that directly
modulate PICALM expression. Rs3851179 is unlikely to be a directly functional
SNP since its well removed from PICALM at 80kbp upstream and does not alter
a transcription factor binding site as predicted by ENCODE (Rosenbloom KR,
2012). Hence, we speculate that another SNP, more proximal to PICALM, is the
functional SNP and is in moderate linkage disequilibrium with rs3851179.

Variation in PICALM expression associated with rs3851179 genotype may
have several effects. At the cellular level, PICALM mediates clathrin-coated-pit
endocytosis; the amino-terminus of PICALM binds phosphatidyl-inositol 4,5
bisphosphate (PIP2), while the central portion binds adaptor protein-2 (AP-2) and
the carboxyl terminus binds clathrin (Meyerholz et al., 2005; Ramanan et al.,
2011a). Reducing PICALM expression by siRNA leads to altered size and shape
of the clathrin-coated pit (Meyerholz et al., 2005; Tebar et al., 1999). Since the
AD-protective allele of rs3851179 correlates with increased PICALM expression,
we considered several mechanisms whereby PICALM may modulate AD risk.
First, PICALM expression modulates APP metabolism in vitro. Decreased
PICALM expression leads to increased APP at the cell surface while increased
PICALM expression leads to increased APP internalization. Since APP is
metabolized in a non-amyloidogenic pathway at the cell surface but in an
amyloidogenic pathway in endosomes, the effects of PICALM on APP
localization lead to altered Aβ levels: PICALM knockdown reduces Aβ while
PICALM overexpression increases Aβ (Xiao et al., 2012). This pathway is not
consistent with our finding that the protective rs3851179 allele increases PICALM
expression.
A second pathway whereby altered PICALM may alter AD risk recognizes
that altered PICALM expression modulates cell surface proteins in a proteinspecific fashion. For example, decreased PICALM leads to increased GluR2
which may promote excitotoxicity (Harel et al., 2011); the protective rs3851179
allele that increases PICALM expression may reduce AD risk by reducing
excitotoxicity. Increased PICALM also leads to increased cell surface transferrin
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and EGFR (Harel et al., 2011; Huang, Khvorova, Marshall, & Sorkin, 2004;
Meyerholz et al., 2005; Tebar et al., 1999). Consistent with a critical role for
PICALM in iron homeostasis, PICALM-deficient mice suffer from severe anemia
and poor erythroid development and, at the cellular level, show reduced
transferrin uptake; iron supplementation ameliorates some aspects of PICALM
deletion (Scotland et al., 2012). Recognizing that PICALM was robustly
expressed in microvessels and that PICALM expression correlated positively with
microvessel mRNAs, we speculate that increased PICALM may be AD-protective
by facilitating Aβ clearance across the blood brain barrier (Sagare, Bell, &
Zlokovic, 2012). Overall, altered PICALM levels may modulate AD risk by
multiple mechanisms and is the subject of ongoing investigation.

Multiple PICALM exons were spliced inefficiently in human brain.
Isoforms lacking many of these exons are likely to encode PICALM with altered
function. Isoforms lacking exon 13 were especially common. Since a critical AP2 binding DPF peptide motif is encoded by exon 13, the loss of exon 13 is
expected to reduce AP-2 binding (Meyerholz et al., 2005). Loss of this DPF motif
may be compensated by the DIF and/or FESVF motifs encoded within exons 12
and 14, respectively (Meyerholz et al., 2005). Isoforms lacking exons 13 and 14
were also detected that would lack both the DPF and FESVF motifs and would
be expected to have particularly low AP-2 binding. Rare isoforms also showed
an absence of exons 2 or 2-4. Since exon 2 is 143 bp, isoforms lacking exon 2
undergo a codon frameshift such that D2-PICALM and D2-4-PICALM are
predicted to encode only an amino terminal PICALM fragment. Since the exon 5
SNP, rs592297, was associated with exon 2 splicing, we sought to evaluate
whether this SNP was associated with AD. Although rs592297 was not available
in data from Naj et al, rs1237230 is highly linked with rs592297 (r2=0.95 in
Europeans, (http://www.broadinstitute.org/mpg/snap/ldsearch.php) and is present
in this dataset. Rs1237230 was modestly associated with AD (p=0.018), relative
to rs3851179 (p=0.00015) (Naj et al., 2011). Hence, rs592297 does not appear
to be robustly associated with AD risk relative to the primary PICALM SNP.
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Although rs592297 may be a functional SNP in modulating exon 2-4 splicing, the
modest proportion of PICALM present in this isoform may mitigate the SNP
effects on overall PICALM function.

Conclusion
In summary, our primary findings are that multiple PICALM isoforms are
expressed in human brain, with prominent presence in microvessels, and that
overall PICALM expression is correlated with the AD SNP rs3851179.

Rare

PICALM isoforms are associated with AD status and / or rs592297, a SNP that is
in moderate linkage disequilibrium with rs3851179. The rarity of these isoforms
and their lack of association with rs3851179 suggest they are unlikely to
contribute to AD risk. Since D13-PICALM is the most abundant PICALM isoform,
future studies of PICALM function may wish to evaluate this isoform.

Acknowledgements: Parts of this chapter have previously published in Parikh,
Fardo, & Estus, 2014
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Figure 2.1 PICALM immunohistochemistry in human brain.

Human anterior cingulate was immunostained with anti-CALM antibody,
revealing robust microvessel labeling (bar=100µm).
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Figure 2.2 Quantitative analysis of PICALM isoform expression.

The indicated mRNAs or isoforms was quantified by qPCR and compared
relative to the AD-associated SNP rs3851179 (A-E) or rs592297, an exon 5 SNP
(F).
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Figure 2.3 PICALM splice patterns in human brain.

PCR amplification across the indicated exons was performed on cDNA pooled
from AD and non-AD brain samples. The products were separated by
polyacrylamide gel electrophoresis and visualized by SYBR-Gold fluorescence.
Single PCR products from amplifications between exon 3-9 and 7-12 indicate
that individual exons between 5-11 are included with high efficiency.

The

presence of multiple products in other lanes represents inefficiently spliced exons
as confirmed in Table 2.3.
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Table 2.1 PCR Primers.

Target

Name

Exons 1-5

1F

Sense

CTGACGGACCGAATCACTG

5R

Antisense

TCAAGAAGTGCATCCATCTGA

3F

Sense

TGGCTTCAAGAAACACGTTG

9R

Antisense

GCTTGCAGCTGTAGAATCTTTG

7F

Sense

TGAAAAAGAACCAATGCAAAGA

12R

Antisense

CCCCATGTACTTGCTACCTGA

10F

Sense

CTTTCCAATGCAGTGTCTTCC

14R

Antisense

CCCCAGAATCTACTACAATAACATTTG

12F

Sense

GCCCAATGATCTGCTTGATT

17R

Antisense

CATTGTTGCAGCATTCCAAG

15F

Sense

GCTTTGATGAACTAGGTGGACTT

20R

Antisense

GCAGTTTGGATTTTGCTGGA

9

Sense

ACAGGCCCCTAGCAGTCTTC

10

Antisense

TGCTTTTCCCTTTCATCCAC

11

Sense

TGCAGCCTCTCCTGTATCCACCT

12-14 Junction

Antisense

GGAGAAGGAGTGAATCCTCCC

17

Sense

TGGAGTCAACCAGGTGAAAA

17-20 Junction

Antisense

CATTTGTGGAGGCATTGTTG

1

Sense

GAGGAGCTGCAGAGATGTCC

1-3 Junction

Antisense

TACTGAATAAAACGAGTCCAGGTG

1-5 Junction

Sense

AAAGCACCTGGACTGGCTGA

6

Antisense

GGCAGCATTTATTACCCCATT

CD31F

Sense

ATTGCAGTGGTTATCATCGGAGT

CD31R

Antisense

CTCGTTGTTGGAGTTCAGAAGTGG

vWF F

Sense

CGGCTTGCACCATTCAGCTA

vWF R

Antisense

TGCAGAAGTGAGTATCACAGCCATC

12

Sense

GCCCAATGATCTGCTTGATT

20

Antisense

TTGGTTGCGTCATTACAGGA

Ex 4

Sense

AAGAGATCCGCACGCAGTAT

Ex 5

Antisense

GTAGTCGTTGGCTTCGTGCT

SYN F

Sense

AGGGAACACATGCAAGGAG

SYN R

Antisense

CCTTAAACACGAACCACAGG

Exons 3-9

Exons 7-12

Exons 10-14

Exons 12-17

Exons 15-20

Total PICALM

D13

D18-19

D2

D2-4

CD31

VWF

Exon12-20

GFAP

SYN

Sequence (5'-3')

PCR primers used for screening splice variants, cloning, qPCR and sequencing.
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Table 2.2 Multivariate Linear Regression Analysis of Total PICALM and
Isoforms.
Standardized

p-value

β Coefficients
Model: Total PICALM Expression
(Adj r2=0.46)
AD Status

-0.05

0.66

Rs3851179

0.298

6.9 x 10-3

Microvessel mRNA

0.387

8.6 x 10-4

SYP mRNA

-0.455

1.2 x 10-4

GFAP mRNA

0.313

0.01

AD Status

-0.304

4.9 x 10-3

Rs3851179

0.268

8.1 x 10-3

Microvessel mRNA

0.302

4.0 x 10-3

SYP mRNA

-0.519

4.2 x 10-6

GFAP mRNA

0.513

1.8 x 10-5

AD Status

0.011

0.94

Rs3851179

-0.036

0.78

Microvessel mRNA

0.255

0.06

SYP mRNA

-0.36

8.0 x 10-3

GFAP mRNA

0.312

0.03

Model: D13-PICALM (Adj r2=0.54)

Model: D18-19 PICALM (Adj r2=0.21)
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Table 2.2, continued.
Model: D2-PICALM (Adj r2=0.41)
AD Status

0.238

0.05

Rs3851179

0.084

0.46

Microvessel mRNA

0.287

0.02

SYP mRNA

-0.429

1.0 x 10-3

0.24

0.06

AD Status

-0.322

0.03

Rs3851179

0.114

0.40

Microvessel mRNA

0.002

0.99

SYP mRNA

0.233

0.10

GFAP mRNA

-0.041

0.79

AD Status

-0.245

0.08

Rs592297

0.384

4.0 x 10-3

Microvessel mRNA

0.004

0.97

SYP mRNA

0.243

0.06

GFAP mRNA

0.001

0.99

GFAP mRNA
Model: D2-4 PICALM (Adj r2=0.10)

Model: D2-4 PICALM (Adj r2=0.24)

Total PICALM, D13-PICALM, D18-19 PICALM, D2-PICALM, and D2-4 PICALM
expression was analyzed as a function of AD, rs3851179 and microvessel
mRNA, SYP and GFAP content by using a linear regression model. D2-4
PICALM was also analyzed as a function of rs592297, along with AD,
microvessel mRNA, SYP and GFAP. Adj: Adjusted
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Table 2.3 Semi-Quantitative PICALM Isoform Analysis.

Rs3851179 Genotype
PICALM Isoforms (exons 12-20)
D13

AA
(%Total Clones)
45.4 ± 5.3

GG
(%Total Clones)
44.0 ± 9.0

D13, 14

1.9 ± 1.6

1.7 ± 1.6

Dp15

1.8 ± 2.2

4.5 ± 4.4

D13, p15

15.3 ± 0.5

16.4 ± 3.2

D13, 18

9.2 ± 4.3

9.3 ± 1.5

D13, p15, 18

5.9 ± 1.8

4.2 ± 0.7

D18

2.8 ± 2.1

3.1 ± 1.8

D13, 18, 19

2.6 ± 2.6

0.9 ± 0.4

D13, p15, 18, 19

3.7 ± 3.3

0.4 ± 0.4

Full Length (12-20)

7.2 ± 3.0

12.6 ± 6.5

Complementary DNA from three rs3851179A/A and three G/G samples was
amplified and the PCR amplicons cloned. A total of 847 random clones were
then sequenced. This table shows the frequencies of each isoform (mean ± SD),
noting that “D” indicates that an exon is missing while “p” designates a partial
exon deletion, i.e., p15 refers to clones lacking first 15 bp of exon 15. Additional
isoforms with an average frequency of less than 1% are not included, including
rare isoforms that lacked the first 21 bp of exon 13.
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Chapter 3
An Intronic PICALM Polymorphism, rs588076, is Associated with Allelic
Expression of a PICALM Isoform
Abstract
Although genome wide studies have associated single nucleotide
polymorphisms (SNP)s near PICALM with Alzheimer´s disease (AD), the
mechanism underlying this association is unclear. PICALM is involved in clathrinmediated endocytosis and modulates Aβ clearance in vitro. Comparing allelic
expression provides the means to detect cis-acting regulatory polymorphisms.
Thus, we evaluated whether PICALM showed allele expression imbalance (AEI)
and

whether

this

imbalance

was

associated

with

the

AD-associated

polymorphism, rs3851179.
We measured PICALM allelic expression in 42 human brain samples by
using next-generation sequencing. Overall, PICALM demonstrated equal allelic
expression with no detectable influence by rs3851179. A single sample
demonstrated robust global PICALM allelic expression imbalance (AEI), i.e.,
each of the measured isoforms showed AEI. Moreover, the PICALM isoform
lacking exons 18 and 19 (D18-19 PICALM) showed significant AEI in a subset of
individuals. Sequencing these individuals and subsequent genotyping revealed
that rs588076, located in PICALM intron 17, was robustly associated with this
imbalance in D18-19 PICALM allelic expression (p=9.54 x 10-5). This
polymorphism has been associated previously with systolic blood pressure
response to calcium channel blocking agents.

To evaluate whether this

polymorphism was associated with AD, we genotyped 3269 individuals and
found that rs588076 was modestly associated with AD. However, when both the
primary AD SNP rs3851179 was added to the logistic regression model, only
rs3851179 was significantly associated with AD.
PICALM expression shows no evidence of AEI associated with
rs3851179. Robust global AEI was detected in one sample, suggesting the
existence of a rare SNP that strongly modulates PICALM expression. AEI was
detected for the D18-19 PICALM isoform, and rs588076 was associated with this
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AEI pattern. Conditional on rs3851179, rs588076 was not associated with AD
risk, suggesting that D18-19 PICALM is not critical in AD. In summary, this
analysis of PICALM allelic expression provides novel insights into the genetics of
PICALM expression and AD risk.

Introduction
Phosphatidylinositol binding clathrin assembly protein (PICALM) facilitates
clathrin-mediated

endocytosis.

PICALM

binds

phosphatidylinositol

4,5-

bisphosphate (PIP2), adaptor protein 2 (AP2) and clathrin to mediate endocytic
clathrin coated vesicle formation at the plasma membrane. Although PICALM is
ubiquitously expressed, PICALM expression is more pronounced in microvessels
(Baig et al., 2010; Parikh, Fardo, et al., 2014). Previous studies have shown
PICALM co-localizes with APP and modulates amyloid beta (Aβ) generation
(D'Angelo et al., 2013; Kanatsu et al., 2014; Xiao et al., 2012). Accumulation of
Aβ deposits is a hallmark of Alzheimer’s Disease (AD) pathology.

Genome wide association studies in multiple cohorts have identified single
nucleotide polymorphisms (SNP)s near the PICALM gene as significantly
associated with AD risk (Harold et al., 2009; Jun et al., 2010; Lambert et al.,
2009; Pedraza et al., 2014; Seshadri et al., 2010). Studies were first conducted
with Caucasian populations and then independently verified in several although
not all Asian populations (Chen et al., 2012; Li et al., 2011; G. Liu et al., 2013;
Miyashita et al., 2013; Yu et al., 2011). These studies report that the rs3851179
A allele reduces AD risk with an odds ratio of 0.88 (Harold et al., 2009). This SNP
is located approximately 80kb 5’ of PICALM.

Understanding how rs3851179 alters PICALM to impact AD risk may lead
to novel insights into AD mechanisms and potential treatments. Since rs3851179
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is not in linkage disequilibrium (LD) with a SNP that alters a PICALM amino acid
(r2<0.1), we hypothesize that rs3851179 is associated with changes in mRNA
transcription or processing. Allelic expression imbalance (AEI) which is an
expression difference between allelic transcripts within an individual, has been
used to detect cis-regulatory effects (Jentarra, Rice, Olfers, Saffen, & Narayanan,
2011; Jones & Swallow, 2011; Mondal, Sharma, Elbein, & Das, 2013; Pham et
al., 2012; Smith et al., 2013).

Here, we performed an AEI analysis by comparing allelic expression
through the use of two exonic SNPs, rs76719109 and rs592297, in AD and nonAD brain samples. These studies included 35 samples that were heterozygous
for rs76719109 and 19 samples that were heterozygous for rs592297. While
PICALM expression did not show AEI overall, one individual showed robust
PICALM AEI, with an allelic ratio of 0.76.

Additionally, significant AEI was

detected for the PICALM isoform lacking exons 18 and 19 (D18-19 PICALM).
Sequencing and additional genotyping established that rs588076 was robustly
associated with this AEI pattern. Interestingly, rs588076 has been associated
with blood pressure response to Ca++ channel blocking agents (Kamide et al.,
2013). We discuss these overall results in the context that genetic regulation of
PICALM isoforms relative to AD risk is highly complex with further work
necessary to elucidate the mechanisms modulating genetic risk.

Materials and Methods
DNA and RNA extraction from human brain tissue
The RNA and DNA samples for this study were from de-identified AD and
non-AD human brain anterior cingulate specimens provided by the University of
Kentucky AD Center Neuropathology Core and have been described previously
(Ling et al., 2012; Malik et al., 2013; Parikh, Fardo, et al., 2014). The overall
dataset included 30 AD samples (14 male, 16 female) and 30 non-AD samples
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(15 male, 15 female). The age at death for individuals that were cognitively intact,
i.e., non-AD, was 82 ± 8 years (mean ± SD, n = 30) while age at death for AD
individuals was 82 ± 6 (n = 30). The average post-mortem interval (PMI) for nonAD individuals was 2.8 ± 0.9 hours (mean ± SD, n = 30) while the PMI for AD
individuals was similar at 3.4 ± 0.6 hours (n = 30). For the rs76719109 AEI
assay, a subset of 35 samples were heterozygous for this SNP and included 18
non-AD (9 male, 9 female) and 17 AD (9 male, 8 female) (Table 3.1, 3.2). For the
rs592297 AEI assay, a total of 19 out of 60 samples were heterozygous, 13 nonAD (7 male, 6 female) and 6 AD (3 male, 3 female) (Table 3.3, 3.4). Preparation
of gDNA, RNA and cDNA was performed as described in previous studies (Ling
et al., 2012; Malik et al., 2013; Parikh, Fardo, et al., 2014). Although RNA
integrity analyses were not performed prior to reverse transcription, others have
demonstrated that for qPCR with short amplicons, normalized expression
differences are comparable between samples with moderate RNA degradation
and those with high integrity RNA (Fleige & Pfaffl, 2006). We recognize that the
absence of RNA integrity analysis constitutes a caveat of this study.

Genotyping and sequencing
DNA samples were genotyped for rs3851179, rs76719109, rs592297 and
rs588076 by using unlabeled PCR primers and two allele-specific TaqMan FAM
and VIC dye-labeled MGB probes (Pre-designed TaqMan SNP Genotyping
Assay, Applied Biosystems) on a real-time PCR machine (Chromo4, MJ
Research PTC-200).

Allelic imbalance assay
Rs76719109 is in exon 17. For AEI analysis with rs76719109, PICALM
was amplified from exon 17 to exon 20 for cDNA and exon 17 to intron 17 for
genomic DNA. For rs592297, PICALM was amplified from exon 5 to exon 6 for
cDNA and exon 5 to intron 5 for genomic DNA. Exon numbering is according to
PICALM-005 ENST00000393346 for exons 1-16 and exons 17-21 correspond to
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the final five exons within PICALM-002 ENST00000532317 in Ensembl, since no
single ENSEMBL transcript includes each of the exons the we identify here (Paul
Flicek). The PCR primers included Ion Torrent adapters, individual barcodes and
DNA sequence flanking the region of interest (Table 3.5). Each PCR reaction
(50uL) contained 1x PCR buffer, 20ng cDNA or 100 ng gDNA, 1uM of forward
and reverse primer, 0.1mM dNTP and 0.5 Units Taq (Platinium Taq, Invitrogen).
Cycles consisted of pre-incubation at 95˚C for 2 minutes, followed by 28 cycles of
95˚C for 15 s, 60˚C for 30s and 72˚C for 60s followed by incubation at 75˚C for 7
minutes. To acquire equal representation from each sample, relative amounts of
PCR product were quantified by subjecting 10 uL of PCR product to
electrophoresis on 7.5% polyacrylamide gels and SYBR gold staining relative to
a Low DNA Mass Ladder (Invitrogen). Approximately 2 ng of each individual’s
cDNA and gDNA PCR products were pooled, purified using Agencourt AMPure
XP and subjected to Ion Torrent sequencing on a Ion Torrent 316 chip (Ion PGM
Sequencer).

Data extraction and analysis of allelic mRNA expression
Allelic counts were extracted from DNA sequences by using Perlscript in a
three-step fashion: (i) sequences corresponding to each sample were separated
based on their barcode, (ii) gDNA and cDNA were then separated based on the
presence of intronic and exonic sequences, respectively, and (iii) allele counts
were obtained by using sequences that bridged the SNP of interest.

Standard curve generation
One rs76719109 homozygous major (GG) and one homozygous minor
(TT) individual was selected based on similar qPCR copy numbers. Five dilutions
were prepared with different ratios of each individual’s cDNA: 1:4, 1:2, 1:1, 2:1,
and 4:1. These samples were PCR amplified and subjected to sequencing as
described above.
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Statistical analysis
Analysis of allelic counts was based upon the assumption that transcript
read counts follow a Poisson distribution (H. Jiang & Wong, 2009). As such,
each allele from the heterozygous SNP was used to define two random
variables. Following the rs76719109 example of a G/T SNP, we denote the pair
of transcript counts as 𝐺 ~ 𝑃𝑃𝑃𝑃𝑃𝑃𝑃 (𝜆𝐺 ) and 𝑇 ~ 𝑃𝑃𝑃𝑃𝑃𝑃𝑃 (𝜆 𝑇 ). That is, G and T
are Poisson-distributed random variables with means 𝜆𝐺 and 𝜆 𝑇 , respectively. It

can then be readily shown that for a given pair of realized transcripts counts, G=g
and T=t, the transcript count of either allele is binomially distributed with success
probability equal to a ratio of component means.
𝑡 ~ 𝐵𝐵𝐵 (𝑔 + 𝑡, 𝑝 = 𝜆

𝜆𝐺

𝐺 +𝜆𝑇

That is, 𝐺 | 𝐺 + 𝑇 = 𝑔 +

). Testing for AEI then simplifies to an examination of the

null hypothesis that the pair of transcript counts comes from the same
1

distribution, i.e., that 𝜆𝐺 = 𝜆 𝑇 , which is equivalent to testing 𝐻0 : 𝑝 = 2 [𝐺 | 𝐺 + 𝑇 =
1

𝑔 + 𝑡 ~ 𝐵𝐵𝐵 (𝑔 + 𝑡, 2)]. This null hypothesis agrees with the intuition that when the

total of transcript counts is known, the number generated from a specific allele is
essentially a sequence of independent, equally probable trials. Thus, rejection of
this null hypothesis corresponds to AEI.

Measuring transcripts from genomic DNA is one way of correcting for the
possibility of differential experimental error between allele transcript counts.
Conceptually, one could adapt methods for determining AEI by an appropriate
adjustment with the ratio of reads from gDNA as these reads should theoretically
come from the same distribution regardless of AEI (Fardo et al., unpublished).
Alternatively, it can be assumed that one allele is derived from a distribution with
an inflated mean solely due to experimental error (i.e., under the null hypothesis
of no AEI). In this case, we have that the means of the transcript reads satisfy
either 𝜆𝐺 = (1 + 𝛿)𝜆 𝑇 or (1 + 𝛿)𝜆𝐺 = 𝜆 𝑇 . Here, the probability parameter, p, for
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the count probability in the AEI test becomes

1+𝛿

2+𝛿

or

1

2+𝛿

, respectively. For our

gDNA data, we have a maximum 8.5% increase of one allele over the other and
chose to conservatively assume a 20% mean increase (i.e., 𝛿 = 0.2). We then
1+𝛿

calculate the AEI test p-value from the lesser-significant test of 𝐻0 : 𝑝 = 2+𝛿 and
1

𝑝 = 2+𝛿.

Genotype association with AD risk
The Mayo Clinic dataset has been described previously (Naj et al., 2011;
Ridge, Mukherjee, Crane, Kauwe, & Alzheimer's Disease Genetics, 2013).
Briefly, the Mayo Clinic dataset contained 1789 cases and 2529 non-ADs
collected from six centers from the US and Europe as described (Naj et al.,
2011). Direct genotyping of rs3851179 and rs588076 was performed using a
TaqMan SNP genotyping assay in an ABI PRISM 7900HT Sequence Detection
System with 384-well block module from Applied Biosystems (California, USA).
First-pass genotype cluster calling was analyzed using the SDS software version
2.2.3 (Applied Biosystems, California, USA). Variants passed Hardy-Weinburg
(P>0.05) and minor allele frequencies are consistent with public databases (EVS,
HapMap, 1000G). Association testing for rs3851179, with and without rs588076,
was carried out in PLINK (Purcell et al., 2007) by using an additive logistic
regression model corrected for appropriate covariates; diagnosis age, APOE ɛ4,
APOE ɛ2, sex and contributing center.

Results
To detect the presence of regulatory cis-acting SNPs in human brain
samples, we measured allelic ratios in cDNA from reverse transcribed mRNA.
Heterozygosity for an exonic “reporter” SNP provides the means to compare the
expression of one allele with another allele within an individual. Our criteria for
reporter SNPs for AEI analysis is that the SNPs are present in exons and have a
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minor allele frequency (MAF) greater than 15%, which allows for sufficient
sample numbers for analysis. Only two PICALM SNPs satisfied these criteria,
rs76719109 and rs592297 (Figure 3.1). Rs76719109 has a MAF of 0.44 and
resides within exon 17; PCR amplification from exon 17-20 allowed us to
measure AEI for total PICALM as well as PICALM splice variants lacking exon 18
or exons 18-19 (Figure 3.1a). Rs592297 has a MAF of 0.20 and resides in exon
5. PCR amplification from exon 5-6 produced a single PCR product for cDNA
(Figure 3.1b). The AEI assay was validated in two ways. First, we tested the
linearity of the assay by generating a cDNA standard curve consisting of five
different rs76719109 T:G ratios (Figure 3.2). Our input T:G ratios ranged from
1:4 to 4:1. We found a robust linear relationship between input and observed
T:G ratios. Second, we applied our experimental approach to gDNA, which
represented a positive control with an expected “allelic” ratio of 1.0. Rs76719109
and rs592297 showed gDNA ratios of 1.01 ± 0.03 (mean ± SD, n=35) and 0.96 ±
0.05 (mean ± SD, n=19), respectively (Figure 3.3). Hence, this AEI assay
appears robust for detecting and quantifying variations in allelic expression.

To evaluate whether the AD-associated SNP rs3851179 was associated
with unequal allelic PICALM expression, we performed AEI analysis with
rs76719109 and rs592297on a total of 54 samples. Twelve of these 54 samples
were heterozygous for both SNPs. Hence, we analyzed PICALM for AEI in a
total of 42 unique individual samples. This effort analyzed 4.2 million sequences
for rs76719109 and 1.4 million sequences for rs592297. If rs3851179 modulated
total PICALM expression, we expected to see significant AEI in individuals
heterozygous for rs3851179, but not in individuals homozygous for rs3851179.
When we analyzed the results for the exon 17 SNP, rs76719109, significant AEI
was observed in only a single sample, termed AD40 (see below). To evaluate
whether a subtle difference in allelic expression may be present and associated
with rs3851179, we compared the mean allelic expression between the
rs3851179 homozygous and heterozygous groups.
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This approach did not

discern a significant difference between the two groups, i.e., the allelic ratios for
rs3851179 homozygous and heterozygous groups was 0.94 ± 0.08 (n=17) and
0.97 ± 0.06 (n=18), respectively (Figure 3.4a, p= 0.24, t-test). Hence, rs3851179
did not appear associated with PICALM AEI. To confirm this finding and extend
the analysis to additional samples, we analyzed allelic expression by using the
exon 5 SNP, rs592297. Significant AEI was not observed in any sample, noting
that the sample with the significant AEI result from the rs76719109 analysis was
homozygous for rs592297 and not suitable for evaluation. When the allelic ratios
were analyzed by t-test to evaluate whether rs3851179 was associated with
allelic expression, the findings confirmed that rs3851179 was not associated with
robust AEI; the allelic ratios were 0.93 ± 0.05 (n= 4) for rs3851179 homozygotes
and 1.01 ± 0.07 (n= 15) for heterozygotes (Figure 3.4b, p= 0.06). Hence, we
found that the total PICALM allelic ratio for each person was remarkably
consistent with both reporter SNPs; rs3851179 is not associated with overall
allelic PICALM expression.

Interestingly, cDNA from the individual termed AD40 showed significant
unequal allelic mRNA expression with a T:G ratio of 0.76 (Figure 3.4a, Table
3.6). This ratio is based on a total of four experiments that detected a total of
68141 copies of the T allele and 88400 copies of the G allele. This AEI was not
due to genomic normalization as the genomic T:G ratio was 1.01. These data are
based upon the rs76719109 SNP because this individual was homozygous for
rs592297. A similar result was obtained when each of four separate replicates
were analyzed individually, i.e., when each replicate was analyzed individually,
the T:G ratio was 0.73 ± 0.04 (mean ± SD). Hence, significant AEI was observed
in a single individual among the 42 unique samples.

Having considered overall PICALM allelic expression, we proceeded to
apply this AEI analysis to PICALM isoforms.
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The exon 17 to exon 20 PCR

amplicons captured three different PICALM isoforms because exons 18 and 19
are variably spliced. These isoforms were termed full length PICALM (contains
exons 18-19), D18-PICALM (lacked exon 18) or D18-19 PICALM (lacked both
exons 18 and 19). We analyzed each of these isoforms for the presence of AEI
as a function of rs3851179 heterozygosity. For the full length PICALM and D18PICALM isoforms, significant AEI was observed only in the AD40 sample. To
evaluate whether a subtle difference in allelic expression may be present, we
compared the allelic expression of the full length PICALM isoform between the
rs3851179 homozygous and heterozygous groups by using a t-test. However,
no difference was observed as the average T:G ratio in the rs3851179
homozygous and heterozygous groups was 0.93 ± 0.07 (n=17) and 0.93 ± 0.06
(n=18), respectively (Figure 3.5a, p= 0.81).

Likewise, for the D18-PICALM

isoform, the rs3851179 homozygous and heterozygous groups showed mean
T:G ratios of 0.95 ± 0.09 (n=17) and 1.01 ± 0.12 (n=18), respectively (Figure
3.5b, p=value= 0.13).

When we evaluated the D18-19 PICALM isoform,

significant AEI was detected in multiple samples (Figure 3.5c). We analyzed
these results in two ways. First, we compared the frequency of samples with
significant AEI between the rs3851179 homozygous and heterozygous
individuals by using a Fisher’s exact test; a significant difference between groups
was not detected (Figure 3.5c, p= 0.44). Second, we compared the mean T:G
ratio between rs3851179 homozygous and heterozygous individuals by using a ttest.

However, the rs3851179 homozygous and heterozygous individuals

showed similar values that did not achieve significance , i.e., 1.19 ± 0.16 and
1.11 ± 0.22, respectively (p=0.08). Hence, rs3851179 heterozygosity was not
associated with AEI for these PICALM isoforms.

We considered the subset of samples that showed significant AEI further.
Among these, AD40 showed significant AEI for each of the isoforms, with the
D18, D18-19 and full length PICALM isoforms having allelic T:G ratios of 0.77,
0.53 and 0.77, respectively. As noted above, this finding is consistent with the
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hypothesis that a rare SNP acts to alter global PICALM allelic expression in this
individual.

Additionally, we noted that the D18-19 PICALM isoform showed

significant AEI for multiple individuals (Figure 3.5c). In these eight individuals,
the rs76719109T allele was expressed more than the G allele with the ratio
ranging from 1.30 to 1.48 (Table 3.7). This is in contrast to AD40 where the T
allele was expressed less than G allele at a ratio of 0.53 (Table 3.6, 3.7).

Since the D18-19 PICALM isoform but not overall PICALM showed AEI in
multiple samples, we hypothesized that a local SNP influences this splice
pattern. To identify this SNP, we sequenced 6400 bp of genomic DNA between
exons 17-20 in C11 and AD33, the two individuals showing the highest AEI ratio
(Table 3.1). We identified several SNPs that were heterozygous in these samples
including rs588076, rs645299, and rs618629. The MAF for these SNPs in CEU
range from 20-31% (Table 3.8). Additionally, these SNPs are in strong LD with
each other (Table 3.8).

Rs588076 and rs618629 reside in intron 17 while

rs645299 is within intron 18.

We genotyped all samples for rs588076. The

frequency of samples showing significant AEI was significantly associated with
rs588076 heterozygosity (Figure 3.5d, p=9.54 x 10-5, Fisher’s exact test). We
interpret these results as strongly suggesting that rs588076, or a SNP in strong
LD with rs588076, is functional by modulating PICALM exon 18-19 splicing.

Since rs588076 is associated with D18-19 PICALM AEI and rs3851179
has been robustly associated with AD, we evaluated the extent that rs588076 is
associated with AD risk. We evaluated 1789 AD and 2529 non-AD individuals
from the Mayo Clinic cohort. Rs588076 was significantly associated with AD risk
when analyzed in a logistic regression model (odds ratio = 0.8413, 95%
confidence intervals (0.7151-0.9898), p=0.0372). However, when rs3851179 was
added to this logistic regression model, only rs3851179 was significantly
associated with AD (Table 3.9). Haplotypic analysis confirmed that the haplotype
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containing both rs588076 and rs3851179 report the same association with AD as
the haplotype containing only rs3851179 (data not shown). Hence, rs588076 is
associated with D18-19 PICALM AEI but not AD risk.

Discussion
The primary findings of this report include (i) overall PICALM expression
shows no evidence of global AEI even when parsed by AD-associated SNPs, (ii)
robust global AEI was detected in one sample, suggesting the existence of a rare
SNP that strongly modulates PICALM expression, and (iii) eight individuals show
AEI for the D18-19 PICALM isoform that is associated with rs588076. However,
rs588076 was not associated with AD risk when considered in a model that also
included rs3851179. In summary, analysis of allelic expression has proved a
useful tool for the evaluation of cis-acting regulatory polymorphisms and AD risk.

A consistent pattern of AEI in overall PICALM expression was not
detected. This was unexpected since Xu et al reported consistent and robust
PICALM AEI (X. Xu et al., 2011). The reason for different results in these two
studies is unclear. The studies are similar in that both used rs76719109 as a
reporter SNP and similar although not identical PCR primers. The studies differ
in that Xu et al used an Asian population while this report studied Caucasians.
One explanation that would account for the difference in the studies was the
presence of a confounding SNP in the Asian population in the genomic primer
sequence because much of the AEI in Xu et al. was due to correction for
imbalance in gDNA (X. Xu et al., 2011), although such a SNP has not yet been
reported.
We previously reported that the AD-associated SNP rs3851179 was
associated with a modest difference in PICALM expression when analyzed
relative to cell-type specific mRNAs; the minor rs3851179A allele appeared to be
expressed modestly higher than the G allele (Parikh, Fardo, et al., 2014). A
46

similar difference was not observed here. One possible interpretation of these
findings is that rs3851179 or its proxy AD SNP acts in a cell-type specific fashion
that was discernible in our analysis that included cell-type specific markers. The
current AEI study had smaller sample size because only the samples that were
heterozygous for rs76719019 or rs592297 were suitable for analysis. However,
this would not be expected to affect the AEI results because they rely upon an
intra-individual analysis. We interpret these results overall as suggesting that the
AD-associated SNP, or its functional proxy, acts in a cell-type specific fashion to
modulate PICALM expression. This cell-type specific action was not detectable in
this AEI study of mRNA derived from multiple cell types.

The second major finding was that robust AEI was detected for all
PICALM isoforms in one individual, arguing for the existence of a rare functional
SNP that strongly modulates total PICALM expression. For this individual, the
rs76719109G allele was consistently more abundant than the T allele for each
PICALM isoform. We hypothesize that AD40 is unique among the 42 samples in
showing AEI because this sample is heterozygous for a causal SNP. If this
causal allele is present in the heterozygous state in 1 of 42 people, this SNP has
a minor allele frequency of ~1.2%. Although current sequencing studies of the
PICALM promoter region have not yet identified candidate functional SNPs for
AEI in this sample, these studies are on-going and a SNP that strongly
modulates PICALM expression would be expected to be a robust AD risk factor.

The third major finding was that the D18-19 PICALM isoform showed
robust AEI.

There was a strong skew towards increased expression of the

rs76719109T allele. Sequencing identified several candidate SNPs including
rs588076, which is 509 bp downstream of exon 17. This SNP was found to be
robustly associated with AEI for D18-19 PICALM. There are three possible ways
rs588076 could influence D18-19 PICALM splicing efficiency: (i) rs588076 is in
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high LD with a functional SNP that modulates splicing, (ii) rs588076 and other
SNPs influence D18-19 PICALM splicing in a cooperative manner, and/or (iii)
rs588076 directly influences splicing. Further studies are necessary to discern
among these possibilities.

The biological significance of the rs588076 association with D18-19
PICALM is complex.

D18-19 PICALM transcripts account for 1-2% of total

PICALM expression (Parikh, Fardo, et al., 2014). Thus rs588076 is significantly
associated with AEI for a PICALM isoform that is relatively rare in brain. Exons
18 and 19 encode a total of 27 amino acids that are part of the carboxyl terminal
region required for clathrin binding and endocytosis (Scotland et al., 2012).
Hence, the protein encoded by D18-19 PICALM is likely to have reduced function
(Scotland et al., 2012). However, rs588076 was not associated with AD risk and
did not enhance the logistic regression model for the rs3851179 association with
AD. This leads us to conclude that the rs588076 and D18-19 PICALM isoform
may be too rare in the brain to influence AD pathogenesis. Interestingly,
rs588076 was recently associated with the blood pressure response to Ca++
channel blocking agents (Kamide et al., 2013). Since rs588076 is associated only
with D18-19 PICALM, we speculate that this isoform may be more abundant in
other tissues and rs588076 actions upon D18-19 PICALM mediate this systolic
blood pressure phenotype.

Conclusion
In summary, analysis of allelic expression has shown that compelling
PICALM AEI was not observed in most brain RNA samples. Strong global AEI
was documented in one sample, suggesting the existence of a rare PICALM
regulatory SNP. A pattern of AEI was clearly discerned for the D18-19 PICALM
isoform and rs588076 was significantly associated with this pattern. Rs588076
was not associated with AD risk although this SNP has been associated with a
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blood pressure-related phenotype. Allele-dependent expression studies may
provide further insights into additional AD-associated polymorphisms.
Acknowledgements: Parts of this chapter has previously published in Parikh,
Medway, Younkin, Fardo, & Estus, 2014.
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Figure 3.1 Rs76719109 and rs592297 AEI assays.
a) For the exon 17 SNP rs76719109, a barcoded forward primer was positioned
in exon 17, and a reverse primer was positioned in intron 17 (genomic samples)
or exon 20 (cDNA samples). b) For the exon 5 SNP rs592297 assay, a barcoded
forward primer was positioned in exon 5, and a reverse primer was positioned in
intron 5 (genomic samples) or exon 6 (cDNA samples).

Copyright © Ishita Jatin Parikh 2014
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Figure 3.2 Linearity of allelic expression assay.
Different proportions of rs76719109 T and G homozygous cDNA were mixed to
test the linearity of the AEI assay. The T:G ratios were 1:4, 1:2, 1:1, 2:1, and 4:1.
An overall linear relationship was found (r2=0.99). The slope was 0.999, i.e., the
assay detected the T and G alleles with equal efficiency. The graphs are plotted
log2 to avoid compression at the lower ratios and thereby better visualize the
data (X. Xu et al., 2011).
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Figure 3.3 Genomic DNA Allelic Ratios.
a-b) The allelic ratio for the gDNA samples for rs76719109 and rs592297 is
shown. None of the samples showed significant AEI with each of the samples
consistently near the expected 1:1 ratio (note that a 1.0 ratio is equal to 0 in log2).
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Figure 3.4 Evaluation of total PICALM AEI with respect to rs3851179.
a-b) Allelic PICALM expression was assessed by rs76719109 or rs592297. Each
individual sample was normalized to its gDNA ratio. Rs3861179 was not
associated with significant AEI, i.e., only one sample (*) showed significant AEI.
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Figure 3.5 Evaluation of PICALM isoform AEI with respect to rs3851179.
The indicated PICALM isoforms were analyzed for AEI as a function of
rs3851179 (a-c) or rs588076 (d). Each allelic ratio was normalized to the
sample’s gDNA ratio. a) The full length PICALM isoform contained exons 18-19
and showed equal allelic ratios, with a non-significant trend towards an increase
in the G allele. b) D18-PICALM showed equal allelic ratios and c) D18-19
PICALM showed significant unequal allelic ratios in 9 samples (* p<0.05), d) The
D18-19 PICALM AEI was associated with rs588076 heterozygosity. This pattern
of significant AEI was not associated with sex, age or AD status (p>0.05).
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Table 3.1 Rs76719019 Assay Non-AD Sample Demographics.
Sample ID

Age

Sex

PMI

MMSE

NIARI

C01

105

Male

3

24

No

C04

80

Male

3.5

28

No

C06

66

Female

4.5

30

No

C07

85

Male

2

30

Low likelihood

C08

84

Female

1.5

13

Intermediate
likelihood

C09

79

Male

2.25

26

Low likelihood

C10

80

Male

3

27

No

C11

75

Female

3.5

29

No

C12

86

Female

2.25

30

Low likelihood

C13

95

Male

1.75

28

No

C17

72

Female

3.75

30

No

C18

91

Female

4

29

No

C19

86

Female

3.75

29

Low likelihood

C20

81

Male

2

30

Low likelihood

C22

82

Male

2.1

29

Low likelihood

C24

75

Male

4

28

High likelihood

C27

84

Female

2.5

30

Intermediate
likelihood

C29

87

Female

2.41

28

Intermediate
likelihood

Age, sex, PMI, MMSE and NIARI demographic of 18 non-AD samples in
rs76719109 AEI assay.
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Table 3.2 Rs76719019 Assay AD Sample Demographics.

Sample ID

Age

Sex

PMI

MMSE

NIARI

AD33

79

Female

3

11.5

High likelihood

AD37

83

Male

4

17.5

High likelihood

AD40

81

Male

3.5

17

High likelihood

AD42

86

Female

4.25

18

High likelihood

AD43

77

Male

3.5

19

High likelihood

AD44

84

Female

3.33

8

High likelihood

AD45

73

Male

2.75

N/A

N/A

AD46

81

Male

3.75

0

High likelihood

AD47

90

Female

2.8

4

High likelihood

AD48

78

Male

3.75

17.5

High likelihood

AD50

69

Male

4

4.5

Yes

AD51

75

Female

2.33

21.5

High likelihood

AD52

95

Male

4

7

High likelihood

AD54

84

Female

5

18

High likelihood

AD57

86

Female

3.25

7

High likelihood

AD59

78

Male

3.5

11

High likelihood

AD60

68

Female

3.25

26.5

High likelihood

Age, sex, PMI, MMSE and NIARI demographic of 17 AD samples in rs76719109
AEI assay.
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Table 3.3 Rs592297 Assay Non-AD Sample Demographics.

Sample ID

Age

Sex

PMI

MMSE

NIARI

C01

105

Male

3

24

No

C02

92

Female

2.3

26

Low
likelihood

C08

84

Female

1.5

13

Intermediate
likelihood

C09

79

Male

2.25

26

Low
likelihood

C10

80

Male

3

27

No

C11

75

Female

3.5

29

No

C13

95

Male

1.75

28

No

C15

77

Male

3.5

28

Low
likelihood

C19

86

Female

3.75

29

Low
likelihood

C20

81

Male

2

30

Low
likelihood

C23

74

Male

4

26

No

C26

89

Female

1.75

30

Intermediate
likelihood

C27

84

Female

2.5

30

Intermediate
likelihood

Age, sex, PMI, MMSE and NIARI demographic of 13 non-AD samples in
rs592297 AEI assay.
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Table 3.4 Rs592297 Assay AD Sample Demographics.

Sample ID

Age

Sex

PMI

MMSE

AD33

79

Female

3

11.5

AD43

77

Male

3.5

19

AD50

69

Male

4

4.5

AD51

75

Female

2.33

21.5

AD54

84

Female

5

18

AD58

90

Male

3.25

12

NIARI
High
likelihood
High
likelihood
Yes
High
likelihood
High
likelihood
High
likelihood

Age, sex, PMI, MMSE and NIARI demographic of 6 non-AD samples in rs592297
AEI assay.
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Table 3.5 PCR Primers for Rs76719109 and Rs592297 AEI Assay.

SNP Assay

DNA

rs76719109 cDNA

Primer Sense

Primer Sequence

Sense

5'CCATCTCATCCCTGCGTGTCTCCGACTC
AGxxxxxTGGAGTCAACCAGGTGAAAA

cDNA

Anti-sense

5'
CCTCTCTATGGGCAGTCGGTGATTTGGTT
GCGTCATTACAGGA

gDNA

Sense

5'CCATCTCATCCCTGCGTGTCTCCGACTC
AGxxxxxTGGAGTCAACCAGGTGAAAA

gDNA

Anti-sense

5'
CCTCTCTATGGGCAGTCGGTGATAGGAGC
TTTTTCAACTCACCA

rs592297

cDNA

Sense

5'CCATCTCATCCCTGCGTGTCTCCGACTC
AGxxxxxTGAACACAGAAAAACTCCTAAA
AA

cDNA

Anti-sense

5'
CCTCTCTATGGGCAGTCGGTGATGGCAGC
ATTTATTACCCCATT

gDNA

Sense

5'CCATCTCATCCCTGCGTGTCTCCGACTC
AGxxxxxTGAACACAGAAAAACTCCTAAA
AA

gDNA

Anti-sense

5'
CCTCTCTATGGGCAGTCGGTGATTCTGTG
AAAACTTGAGGTTAAAAA

“xxxxx” denotes 5 nucleic acid barcode, which is unique for each individual. Note
that gDNA and cDNA were amplified by the same barcoded forward primers.
Genomic DNA and cDNA were differentiated by the reverse primers.

59

Table 3.6 PICALM AEI Analysis of AD40 Shows Significant Unequal
Rs76719109t To G Allele Ratios.

mRNA ratio
Rs76719109

Counts

Ratio (T/G)

normalized
to genomic

P-value

ratio
Genomic G Allele

40357

Genomic T Allele

40880

mRNA G Allele

88400

mRNA T Allele

68141

1.01

0.89

0.77

0.76

6.76 x 10-58

0.78

0.77

3.63 x 10-09

0.54

0.53

1.96 x 10-65

0.78

0.77

1.88 x 10-30

Isoforms
D18 G Allele

17777

D18 T Allele

13909

D18-19 G Allele

4103

D18-19 T Allele

2203

Full length G Allele

66520

Full length T Allele

52029

Genomic DNA analysis shows an overall equal allelic representation while mRNA
analysis shows significant AEI.

This AEI was present in each of the three

isoforms.
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Table 3.7 D18-19 PICALM Shows Significant AEI in Nine Samples.

D18-19 T:G

Ratio

Counts

(Normalized to genomic ratio)

C01

2337:1793

1.30

8.66 x 10-3

C11

13415:9508

1.47

7.91 x 10-34

C20

745:523

1.43

2.78 x 10-3

AD33

6136:4162

1.48

7.06 x 10-25

AD43

1743:1321

1.31

9.47 x 10-3

AD50

1529:1080

1.41

3.05 x 10-5

AD51

5530:4243

1.33

5.27 x 10-5

AD54

8893:6548

1.38

2.64 x 10-14

AD40

2203:4103

0.53

1.96 x 10-65

Sample

P-Value

These D18-19 PICALM T:G allelic counts are the summation of three separate
runs. AD samples are designated by an AD prefix while non-AD samples are
designated with a C prefix.
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Table 3.8 Samples with Robust AEI are Heterozygous for Three SNPs.

MAF in

LD with

LD with

LD with

LD with

SNP

CEU

rs3851179

rs588076

rs645299

rs618629

rs588076

0.199

0.336

-

0.539

0.911

rs645299

0.306

0.665

0.539

-

0.525

rs618629

0.242

0.319

0.911

0.525

-

The samples C11 and AD33 were sequenced from exon 17 through exon 20.
The samples were heterozygous for the indicated SNPs. These SNPs are in
strong LD (Johnson et al., 2008) with each other and have similar frequencies
for the minor allele (Sherry et al., 2001).
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Table 3.9 Logistic Regression Modeling Of Rs3851179 and/or Rs588076
Effect(s) on AD.

Model

SNP

Odds Ratio

Confidence Interval

P value

rs588076

rs588076

0.8413

0.7151 - 0.9898

0.0372

rs3851179

rs3851179

0.7786

0.6819 - 0.8891

0.0002

rs3851179 + rs588076

rs3851179

0.7767

0.6604 - 0.9136

0.0023

rs3851179 + rs588076

rs588076

1.005

0.8238 - 1.227

0.959

In addition to the indicated SNPs, these models were adjusted for age of onset,
APOE alleles, sex and contributing center.
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Chapter 4
Discussion and Future Studies

Primary Findings
Recent AD GWAS have identified SNPs in several genes involved in
receptor endocytosis. Several of these SNPs, including rs3851179, are near the
gene phosphatidylinositol-binding clathrin assembly protein (PICALM) (Harold et
al., 2009; Jun et al., 2010; Lambert et al., 2009; Pedraza et al., 2014; Seshadri et
al., 2010). It is unclear how PICALM is involved in AD pathogenesis, thus a
greater understanding of underlying molecular mechanisms of PICALM is
needed. In this study I have characterized PICALM expression and splicing in
human brain to help elucidate how this gene can be associated with AD.

The complexity of PICALM expression and splicing necessitated a
complex analysis. PICALM is a ubiquitously expressed protein, which is highly
expressed in brain tissue. Although PICALM is more prominent in microvessels,
it is also present it neurons, astrocytes and oligodendrocytes (Baig et al., 2010;
Bushlin et al., 2008; Parikh, Fardo, et al., 2014). PICALM mRNA expression is
associated with AD risk SNP genotype, rs3851179, when cell type variation is
included in the analysis. Furthermore, there are multiple splice variants present in
the brain. Abundance of the splice variants expressed in brain was quantified by
qPCR. The most abundant splice variant lacks exon 13, followed by exon 18-19,
exon 2 and exon 2-4. It is critical to grasp an understanding of these splice
variants as they will facilitate a better understanding of the molecular
mechanisms influencing functionality of the protein.

An allelic expression imbalance (AEI) study was conducted to further
study the association between rs3851179 and PICALM. Overall, the AD
associated SNP rs3851179 does not demonstrate a detectable effect on global
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PICALM AEI. However, a genetic variant, rs588076, subtly modulates a PICALM
isoform lacking exons 18 and 19. Furthermore, an individual sample shows
PICALM AEI.

These results collectivity signify the intricacy of PICALM

expression in the brain and thereby provide insights into current AD-related
mechanisms studies, which have been largely conflicting and inconclusive.

Discussion and Future Directions
There are multiple implications of the presented findings. First, total mRNA
PICALM expression was quantified using qPCR. Association of PICALM
expression with rs3851179 was only seen when the statistical model was
corrected with different cell type markers, i.e., neurons, astrocytes and
microvessels, as covariates. The linear relationship between PICALM and
different cell type markers is consistent with the immunohistochemical (IHC)
results, where PICALM was present in microvessels and other cell types. The
epitope for this particular antibody is the last 18 amino acids in the carboxylterminus of the protein, which is present in all isoforms of PICALM. Although
several studies have tried to characterize and associate PICALM protein
expression to AD phenotype in AD brains and AD animal models, only few
studies have characterized mRNA expression (Allen et al., 2012; Baig et al.,
2010; Karch et al., 2012; Parikh, Fardo, et al., 2014; Thomas et al., 2011). Allen
et al, Baig et al and Karch et al did not detect an association between PICALM
and AD, similar to our results. We analyzed the relationship between AD risk
SNP, rs3851179, and mRNA expression. The rs3851179A allele is associated
with increased mRNA expression; however, this expression may be modulated
by the polymorphism in a cell-type specific manner because discerning the
association between PICALM expression and rs3851179 was contingent upon
including microvessel mRNA as a covariate within the regression model.
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PICALM has been shown to be involved in intracellular trafficking, synaptic
function and clathrin coated vesicle assembly (Harel et al., 2011; Harel, Wu,
Mattson, Morris, & Yao, 2008). Currently, functional studies primarily focus on
APP processing and subsequent toxic Aβ production to elucidate the role of
PICALM expression in AD pathology (Kanatsu et al., 2014; Treusch et al., 2011;
Xiao et al., 2012). Within the amyloidogenic pathway, APP is endocytosed from
plasma membrane via CME and cleaved by secretase to produce toxic Aβ
(Nordstedt, Caporaso, Thyberg, Gandy, & Greengard, 1993). The protective
allele is associated with increased expression of the gene. Assuming mRNA
expression is comparable to protein expression, increased expression of
PICALM has been shown to influence the size and shape of the clathrin coated
vesicle, as well as reduced function (Meyerholz et al., 2005; Tebar et al., 1999).
Reduction in endocytosis of APP results in reduced Aβ release (Koo & Squazzo,
1994). In yeast and in rat neurons, PICALM has been shown to alter Aβ toxicity.
Increasing PICALM decreased Aβ toxicity in a dose dependent manner (Treusch
et al., 2011). Two other in vitro studies have shown opposite effect of increased
PICALM, where increased PICALM expression, increased Aβ release as a result
of increased APP endocytosis or increased gamma secretase endocytosis
(Kanatsu et al., 2014; Xiao et al., 2012). However PICALM may not be the only
culprit, AP180 is a homologue of PICALM and present exclusively in neurons.
AP180 is also an accessory protein for CME and performs similar function. When
PICALM and AP180 were decreased by RNAi by Wu et al. only AP180
knockdown affected Aβ generation (Wu, Matsuoka, Mattson, & Yao, 2009).
PICALM and AP180 may compensate for one another in neurons or they may be
dedicated to different processes in neurons (Bushlin et al., 2008; Wu et al., 2009;
Wu, Mattson, & Yao, 2010).

PICALM is also present in microvessels, microglia and astrocytes (Ando et
al., 2013; Karch et al., 2012; Parikh, Fardo, et al., 2014). The functional role of
PICALM in these cell types is not well characterized. Our data show that PICALM
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is highly expressed in microvessels and correlates positively with endothelial cell
markers.

This high localized expression suggests that PICALM actions in

microvessels may be critical to PICALM actions in AD. One possible functional
role for PICALM in microvessls Aβ clearance through the blood brain barrier.
Theoretically, Lipoprotein Receptor-related Protein 1 (LRP1) can bind to Aβ in
the brain and transport Aβ into the bloodstream by CME and exocytosis (Deane
et al., 2004; Harasaki, Lubben, Harbour, Taylor, & Robinson, 2005). LRP1 can
bind to Aβ indirectly thorough APOE (Bu, 2009). In one GWAS, PICALM showed
significant reduced risk for AD when corrected for APOE4 genotype, suggesting
a link between APOE and PICALM (Jun et al., 2010; Sweet et al., 2012).
Increased PICALM expression, may increase CME of APOE-Aβ complex bound
to LRP1, promoting clearance of Aβ. An association between CSF Aβ42 level
and PICALM AD risk SNP, further support this hypothesis (Schjeide et al., 2011).
However, APOE and CSF Aβ42 level did not associate with rs3851179 in
replication study and further meta-analyzes study (Kauwe et al., 2011; Naj et al.,
2011).

Implications of splice variants on function
I have identified over 20 different splice variants for PICALM. The role of
PICALM protein encoded by these variants has not been thoroughly researched.
Several isoforms lack key domains and protein binding motifs needed for proper
function. There are three sites important for AP2 binding. Meyerholz et al. have
described the importance of these sites and their effect on PICALM function in
clathrin cage formation and size. The most abundant PICALM isoform lacks exon
13, which encodes a DPF binding motif that binds to AP2 (Meyerholz et al.,
2005). Similarly, some isoforms lack exons 18-19 which encode a protein domain
that is important for clathrin binding (Scotland et al., 2012). Lastly, isoforms that
lack exon 2 have a premature stop codon and encode a truncated PICALM
fragment (Figure 1.2). There are multiple adaptor and accessory proteins
involved in CME which may enable PICALM to be still functional in different
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processes, such as cell proliferation, endosome transport, and vesicle transport
(Dreyling et al., 1996; Meyerholz et al., 2005; Scotland et al., 2012; Tebar et al.,
1999). Different isoforms could be important for different processes. PICALM
bound to AP2 has been shown to be involved in degradation of the APP carboxylterminus fragment, isoforms lacking exon 13 and/or 14 could influence this
process since isoforms lacking these exons would encode a protein with reduced
AP2 binding capability; whereas isoforms lacking exons 18-19 could reduced
endocytosis of APP from plasma membrane since isoforms lacking exons 18-19
would have reduced clathrin binding and subsequently reduced CME (Tian,
Chang, Fan, Flajolet, & Greengard, 2013; Xiao et al., 2012). Endocytosis studies
with protein encoded with these PICALM variants isoforms could lead to a better
understanding of the criticality of these variants.

PICALM isoforms can be cell type specific or the level of expression may
be cell type specific. Our results show that D13, D18-19, and D2 isoforms
correlate positively with microvessel mRNA and GFAP, but negatively with SYN;
whereas the D2-4 isoform correlates positively with neuronal marker SYN (Table
2.2) This means exons 2-4 could be preferentially spliced by neurons to produce
D2-4. Although D2-4 is a rare isoform, it produces a truncated protein that would
be non-functional. When Ando et al. used three different antibodies to stain
PICALM in human brain tissue, the antibody binding the epitopes encoded within
exon 10, exon 13, and last 18 amino acids of the carboxyl-terminus had different
immunoreactivity between the three antibodies (Ando et al., 2013). Our results
indicate that HPA019053 antibody should label stronger in neurons that the other
two antibodies. The expression and function of these isoforms in specific cell
types warrant more investigation.
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Genetic association with splice variants
The relationship between the primary AD-associated SNP and the SNPs
that are associated with PICALM splice variants requires further clarification.
The primary PICALM AD risk SNP is rs3851179. However two other genetic
variations have associated with PICALM isoforms. The first of these SNPs is
rs592297, which associated with D2-4 PICALM isoform in our linear regression
analysis. Rs592297 is a synonymous SNP located within exon 5 and has been
predicted to be an exon splicing enhancer (Harold et al., 2009; Schnetz-Boutaud
et al., 2012). Further experimentation is needed to elucidate if rs592297 is a
functional SNP influencing exon2-4 splicing. If rs592297 is a functional SNP, the
protein encoded by D2-4 PICALM is incomplete and most likely non-functional.
This is a rare isoform and the SNP was not robustly associated with AD in GWAS
(Harold et al., 2009). The impact of this SNP may be low but it could contribute to
AD risk is a cumulative fashion with rs3851179.

The second SNP that was associated with a PICALM isoform was
rs588076, which was associated with the D18-19 PICALM isoform. Rs588076 is
an intronic SNP located within intron 17. Rs588076 may be the functional SNP or
may be in high LD with the functional SNP to influence splicing of D18-19
isoform. Eight out of fourteen individuals, heterozygous for rs588076, showed
significant AEI for D18-19 PICALM. A replicate study with more individuals would
be beneficial. The SNP itself may not be the functional SNP, rather it may work
synergistically with another SNP to influence splicing of exons 18 and 19 or it
may be in high LD with the functional SNP. There were other SNPs within the
latter part of the gene that were heterozygous in individuals showing high AEI.
Most of the SNPs were in high LD with each other, thus multiple SNPs could be
influencing the splicing of exons 18-19 synergistically. Overall, the effect of
rs588076 on D18-19 PICALM should be further studied to elucidate if rs588076
is the functional SNP, or another SNP in high LD with rs588076 is the culprit, as
it may have functional implications beyond AD.
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Isoforms lacking exons 18-19 encode PICALM that lacks a part of the
clathrin binding domain of PICALM. How the loss of exons 18-19 translates to
PICALM function should be further examined. Interestingly, rs588076C allele has
been associated with systolic blood pressure response to calcium channel
blocking drug in hypertensive patients (Kamide et al., 2013).

There is

ambiguouity about how PICALM SNP can be involved in pressure response,
calcium channel regulation or calcium uptake. To gain greater insight, mRNA
expression of total PICALM and D18-19 PICALM should be quantified in vascular
and heart tissue. When we quantified the isoform in brain tissue it was 1-2% of
total PICALM expression. However this isoform may be expressed more in other
tissues. Furthermore, function of the encoded D18-19 PICALM protein should be
studied relative to vascular smooth muscle cells and factors that influence
vasodilation of arteries.

Analysis of SNP effect
Two primary methods were used to analyze the genetic effect of the AD
risk SNP rs3851179 on gene expression. First, real time quantitative PCR
(qPCR) was used to quantify mRNA expression of total PICALM and several
splice variants, and then statistically analyzed for an association with AD,
rs3851179, and brain specific cell types. Second, next generation sequencing
was used to measure the incidence of SNP alleles to see if alleles are unequally
represented, i.e., whether one allele is associated with higher expression of the
gene. Both methods have their strengths and weaknesses. Selected aspects will
be discussed more thoroughly below. In brief, the strengths of the qPCR assay
include: the ability to analyze SNPs in intronic and non-coding region, quantifying
the gene expression with respect to control genes and standard curve, and
sensitive analysis of low expression genes. Conversely, the weaknesses of
qPCR include: inter-individual variability can confound analysis and the ability to
quantify only one isoform in an assay. Whereas, the AEI study assay can detect
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multiple isoforms and avoids inter-individual variability by comparing with a
person. However, the weaknesses of AEI studies includes that the assay
requires that the genes have a higher expression, a common SNP in the coding
region of the gene that is detectable with an amplicon of the appropriate size for
sequencing.

Intronic or noncoding SNPs can be indirectly studied using the AEI
method by using marker SNPs within the gene that are in high LD with the SNP
of interest. Whereas in the qPCR method, any SNP, coding and noncoding, can
be genotyped and can be analyzed for an association directly. We genotyped
rs3851179 in our sample set, and quantified PICALM using qPCR for the
association. Whereas, for the AEI study we used two exonic SNP rs76719109
and rs592297 as marker SNPs and then further analyzed the data for the AD
associated SNP. To analyze SNP effect on gene expression, AEI assays require
exonic SNPs that are sufficiently abundant to ensure numbers of samples that
are well powered for analysis.

Another advantage of qPCR is the sensitive quantification of copy
numbers, whereas in AEI the gene expression is not quantified, rather it is the
relative comparison of transcript or allele present within the sample. With qPCR,
expression of PICALM can be compared among isoforms of PICALM as well as
other genes in the brain; which was especially beneficial to us since our results
showed a cell type effect. We could only compare PICALM expression to SYN,
GFAP and microvessel mRNA using the qPCR method. A common concern with
PCR-based assays is PCR bias. However in both our qPCR and AEI studies, we
included standard curves which were linear and hence PCR bias does appear to
be an issue in our studies. In particular however, we note that we did not
compare the relative abundance of one transcript to another transcript in the AEI
studies because of concerns regarding PCR bias between isoforms in this assay.
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AEI is useful for initial assessment of allele expression, however for more
multidimensional assessment, qPCR analysis is necessary.
Another consideration is amplicon size limitations which are present in
both methods. Although next generation sequencing methods have advanced in
amplicon length reads, at the time our study the average length read was around
150-200 bp by Ion Torrent. In qPCR, the amplicons must be less than 200 bp to
ensure high efficiency amplification. Using qPCR, only one isoform can be
analyzed at a time. Whereas, with the AEI approach, we were able to analyzed
three different isoforms in one study. Overall, experimental design was a
challenge for qPCR and AEI, as there were multiple exons that were alternatively
spliced.

In our results, we see an association of rs3851179 on total PICALM
expression using qPCR, however we do not see equal allelic representation in
the AEI study. These results have two interpretations. First, the qPCR assay
relies upon normalizing the mRNA copy numbers for housekeeping genes, and
cell type specific markers. For ubiquitously expressed genes, this normalization
can be beneficial in discriminating cell specific effects. qPCR analyses are
advantageous in discerning gene effect on expression of a gene present in
multiple cells. PICALM is expressed in endothelial cells, microglia, astrocytes and
neurons. The effect of the SNP on gene expression could be more in one type
than other due to differences in transcription or splicing factors. Normalizing to
these cell types could help discover an association. In AEI study, samples are
normalized to the genomic allelic ratio and there is no cell type or housekeeping
gene normalization. As an example, consider the possibility that PICALM is
highly expressed in microvessels where there is no SNP effect, compared to
expression in neurons where there is a SNP effect but there is low copy number
of the gene. The SNP effect will be masked by the allelic representation of
microvessel cells mRNA content, because all cells are homogenized in the
sample. The second of the different results obtained with the qPCR and AEI
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studies was that the association of PICALM expression with rs3851179 by qPCR
relies upon statistical association. The statistical association could be due to an
unknown confounding factor such that the linear regression analysis of qPCR
results is a statistical artifact.

PICALM in human disease
PICALM has been implicated in two human diseases, acute leukemia and
AD. PICALM was first isolated from the U937 cell line used to study acute
leukemia. Chromosomal translocation of t(10;11)(p13;q14) results in AF10/CALM
or CALM/AF10 fusion gene and is associated with poor prognosis (Ben Abdelali
et al., 2013; Dreyling et al., 1996). The role of the fusion protein in leukemia is
still being elucidated. There are multiple splice variants present for both genes. In
the PICALM/AF10 chromosomal translocation, the chromosome breakpoint
occurs in the latter part of PICALM, usually around intron 17-19 with the resulting
mRNA encoding in frame and out of frame transcripts (Silliman et al., 1998).
(Caudell & Aplan, 2008). Although the fusion transcript is rare, the effect of
rs588076 on exon 18-19 splicing may be critical for the translated leukemogenic
protein.

PICALM is one of the few genes associated with AD through GWAS. AD
is a complex disease with complex genetic penetrance. PICALM locus has been
consistently associated with AD, however, there has been debate if PICALM
SNPs are protective in all populations and/or if rs3851179 is the primary AD
associated SNP for the gene (Harold et al., 2009; Naj et al., 2011; W. Xu, Tan, &
Yu, 2014). It is unclear how the SNP maybe be contributing to the GWAS
outcome. A number of studies have expounded the role of the PICALM protein in
AD pathological pathway. However, few studies have tried to elucidate the
function of the AD SNP genotype in regulating expression and splicing of
PICALM. The SNP itself is ~80,000 bp from the coding region of the gene,
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suggesting that this SNP may be in LD with the functional SNP within the gene,
in the PICALM promoter region, and/or located on a distant-acting transcriptional
regulatory element.

To understand the effect of the SNP on AD, the effects of the AD
associated SNP on PICALM mRNA must be elucidated. The rs3851179A minor
allele is protective for AD risk. Our qPCR results show that presence of A allele is
associated with increased total PICALM and D13-PICALM expression. I interpret
these results as having two possible meanings. The first interpretation focuses
on total PICALM. An increase in total PICALM expression results in increased
PICALM expression, which disrupts CME by altering clathrin coated vesicle size
and shape. This, in turn, reduces endocytosis of proteins like transferrin. In
contrast, increased PICALM has ben shown to increase encocytosis of proteins
like APP, leading to increased Aβ production (Tebar et al., 1999; Xiao et al.,
2012). Thus, increased PICALM could result in a loss of function, as shown by
Tebar et al., because disruption of CME reduces transferrin endocytosis.
However, increased PICALM could be a gain of function resulting in increased
Aβ. The effect of PICALM may be in modulating in a ligand specific manner. The
second interpretation of the SNP association focuses upon increased D13PICALM expression. This would result in increased PICALM protein that has
reduced functional capability and thus decreased CME. Hence, the protein
encoded by isoforms lacking exon 13 needs to further studied within the AD
pathway. Overall, there is still debate whether overexpression of PICALM
exacerbates or rescues AD phenotypes or pathology.

Further studies with

different protein isoforms could elucidate PICALM function in AD.

One would hope that understanding how rs3851179 modulates PICALM
expression and splicing to influence AD risk may allow us to develop novel
therapeutics that mimic the protective effects of this SNP, and thereby reduce AD
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risk. However this will be challenging because PICALM is ubiquitously expressed
and endocytosis is a critical process for many physiological processes.
Furthermore, alterations in PICALM expression have varied results on clathrin
coated vesicle size and shape and CME (Meyerholz et al., 2005; Tebar et al.,
1999). Up regulating or down regulating PICALM might require a fine balance
rather than sheer expression changeability. Evaluating actions of AD associated
SNP on PICALM expression and subsequent protein expression will determine
the effects of encoded isoforms on CME and thereby provide insights into ADrelated mechanisms.

Copyright © Ishita Jatin Parikh 2014
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